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7ABSTRACT
The effects of milk products and milk protein-derived peptides on blood
pressure and the development of hypertension were investigated. In addition,
the effect of milk peptides on arterial function was evaluated. The mechanisms
underlying these effects of milk products and peptides were studied.
Spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto (WKY)
and Wistar rats were used in these experiments.
α-Lactorphin (Tyr-Gly-Leu-Phe), a synthetic tetrapeptide originally derived from
milk whey protein α-lactalbumin, dose-dependently lowered blood pressure
after single subcutaneous administration in adult SHR and WKY. The
antihypertensive effect of this peptide was abolished by opioid receptor
antagonist naloxone, suggesting an involvement of opioid receptors in the
action of α-lactorphin. β-Lactorphin (Tyr-Leu-Leu-Phe), a synthetic tetrapeptide
originating from milk whey protein β-lactoglobulin, also elicited an
antihypertensive effect in SHR after subcutaneous administration.
Since α-lactorphin lowered blood pressure, it was also of interest to investigate
whether α-lactalbumin could influence blood pressure in SHR. However, long-
term oral administration of α-lactalbumin or peptic hydrolysate of α-lactalbumin
did not influence the development of hypertension in young SHR.
In mesenteric arterial preparations of adult SHR, α-lactorphin and β-lactorphin
improved endothelium-dependent relaxation response to acetylcholine (ACh).
This effect was partly mediated via nitric oxide (NO) since NO synthase inhibitor
NG-nitro-L-arginine methyl ester (L-NAME) abolished the improved relaxation
response. Cyclooxygenase (COX) inhibitor diclofenac and non-selective
potassium channel inhibitor tetraethylammonium tetrahydrate (TEA) did not
influence the improved relaxation response in the presence of the peptides,
suggesting that neither vasodilatory prostanoids nor hyperpolarization were
involved. β-Lactorphin also improved the endothelium-independent relaxation
8induced by sodium nitroprusside (SNP). α-Lactorphin and β-lactorphin had no
effects on arterial function in WKY.
Long-term oral intake of synthetic tripeptides IPP (isoleucine-proline-proline)
and VPP (valine-proline-proline), which have originally been derived from milk
caseins, attenuated the development of hypertension in young SHR. A similar
effect was seen after long-term intake of fermented milk products containing the
tripeptides. Fermented milk products also raised plasma renin activity. In a
functional bioassay of angiotensin-converting enzyme (ACE) inhibitory activity
in rat mesenteric arterial preparations, IPP inhibited angiotensin I-induced
contraction but did not affect angiotensin II-induced contraction. These results
suggest that ACE inhibition is involved in the antihypertensive effect of
fermented milk products containing IPP and VPP. However, other factors, such
as calcium, may have contributed to the effect since long-term intake of
fermented milk products attenuated the development of hypertension more than
the intake of tripeptides alone.
In conclusion, fermented milk products and milk protein-derived peptides
lowered blood pressure, improved arterial function and attenuated the
development of hypertension in SHR. In the acute antihypertensive effect of
α-lactorphin, opioid receptors were involved. The improved endothelium-
dependent vasorelaxation in SHR induced by α-lactorphin and β-lactorphin in
vitro was mediated at least partly by NO. The attenuated development of
hypertension in young SHR after long-term intake of milk protein-derived
tripeptides IPP and VPP or fermented milk products containing the tripeptides
may be caused by the ACE inhibitory activity of IPP and VPP. However, other
factors, such as calcium, may also be involved in the action of fermented milk
products.
91 INTRODUCTION
Hypertension is a major risk factor for cardiovascular diseases, such as
coronary heart disease, congestive heart failure and stroke. By lowering high
blood pressure with antihypertensive treatment, the incidence and severity of
these complications can be decreased. In addition to pharmacological
treatment, changes in lifestyle factors have beneficial effects in the treatment of
elevated blood pressure and its complications. These factors may also have a
favourable role in the prevention of hypertension. Non-pharmacological
treatment of hypertension includes diminished use of salt (sodium chloride,
NaCl) and alcohol, and decreased overweight. Increased intake of potassium,
magnesium and calcium may also be advantageous. Recent recommendations
for prevention and treatment of hypertension, e.g. the Sixth Joint National
Committee Report on detection, evaluation and diagnosis of high blood
pressure (Joint National Committee 1997), recommendations by the World
Health Organization and the International Society of Hypertension (Chalmers et
al. 1999), as well as by the Finnish Hypertension Society (2002), emphasize the
role of non-pharmacological therapy, which should also be considered the
foundation for treating hypertensive patients receiving antihypertensive
medication.
Some epidemiological evidence exists that consumption of milk and other dairy
products is associated with reduced blood pressure (Ackley et al. 1983; Garcia-
Palmieri et al. 1984; McCarron et al. 1984; Reed et al. 1985; Trevisan et al.
1988; Abbott et al. 1996; Iso et al. 1999). Furthermore, increased consumption
of milk products has lowered blood pressure in some intervention studies
(Bierenbaum et al. 1987, 1988; Zemel et al. 1988; van Beresteijn et al. 1990;
Buonopane et al. 1992; Appel et al. 1997). It is, however, difficult to relate any
specific component of dairy products to the reduction of blood pressure since
milk products are rich in calcium, potassium and magnesium, and low in
sodium. In addition to electrolytes, milk is a good source of protein. High intake
of dietary protein has been associated with reduced blood pressure levels
(Reed et al. 1985; Stamler et al. 1996a, 1996b). Moreover, dietary proteins can
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be enzymatically degraded to peptide fragments. Some milk protein-derived
peptides have been reported to lower blood pressure (for reviews, see Takano
1998; Shah 2000).
The purpose of the present study was to investigate in spontaneously
hypertensive rats (SHR), an experimental model of essential hypertension,
whether milk products and milk protein-derived peptides can influence blood
pressure or the development of hypertension. The effect of milk protein-derived
peptides on arterial function was evaluated. The studies aimed at clarifying the
mechanisms by which these peptides elicit their effects.
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2 REVIEW OF THE LITERATURE
2.1 MILK AND BLOOD PRESSURE
Epidemiological evidence implies that consumption of milk and other dairy
products is inversely related to blood pressure and the risk for hypertension
(Table 1). The first National Health and Nutrition Examination Survey
(NHANES I), a cross-sectional study with over 10 000 persons in the USA,
found that a diet low in dairy products was predictive of hypertension
(McCarron et al. 1984). Other large cross-sectional American or Italian
population studies also found that consumption of whole milk was
significantly lower in hypertensive than normotensive persons (Ackley et al.
1983; Trevisan et al. 1988). A cross-sectional study reported that Puerto
Rican middle-aged men who drank no milk had two times the prevalence of
hypertension of those consuming at least one litre of milk daily (Garcia-
Palmieri et al. 1984). Another cross-sectional study with over 6 000 middle-
aged men of Japanese ancestry living in Hawaii (Honolulu Heart Program)
found that milk consumption was inversely associated with both systolic
(SBP) and diastolic blood pressure (DBP) (Reed et al. 1985). In a 22-year
follow-up of over 3 000 men in this cohort, non-drinkers of milk had twice the
rate of thromboembolic stroke as compared with those who consumed half a
litre of milk daily (Abbott et al. 1996). Intake of calcium from non-dairy
sources was not associated with the reduced stroke risk, suggesting that
other constituents of milk may be important. An inverse association between
the risk of ischaemic stroke and dietary calcium intake was observed in a
large prospective Nurses’ Health Study with over 85 000 middle-aged
American women (Iso et al. 1999). The increase in the risk of ischaemic
stroke was limited to women with low calcium intake (<600 mg/d). The
inverse association was stronger for dairy calcium than for non-dairy calcium.
However, the relation between dairy calcium intake and reduced risk of
hypertension or stroke has not been found in all epidemiological studies. A
small cross-sectional study with 300 women reported no significant association
TABLE 1. Epidemiological studies on consumption of dairy products and blood pressure.
Country Population Design Main results Reference
USA 5 050 M+F cross- Whole milk consumption was lower in hypertensive than in normotensive men. Ackley et al. 1983
30−79 y sectional Low dairy calcium intake was associated with elevated BP in men.
USA 10 372 M+F cross- Reduced consumption of dairy products was related to hypertension. McCarron et al. 1984
(NHANES I) 18−74 y sectional
Puerto Rico 7 932 M cross- Milk consumption was inversely associated with hypertension. Garcia-Palmieri et al. 1984
45−64 y sectional An increment of approximately 500 ml milk/d was estimated to be
equivalent to a 2 mmHg decrease in SBP.
Hawaii 6 496 M cross- Milk consumption was inversely associated with SBP and D BP. Reed et al. 1985
(Honolulu Heart Program) 55−68 y sectional Dairy calcium intake was inversely associated with BP, non-dairy calcium was not.
USA 308 F cross- Intake of dairy calcium was not associated with BP. Sowers et al. 1985
20−80 y sectional
Italy 5 049 M+F cross- Daily consumption of whole milk was inversely associated with SBP. Trevisan et al. 1988
20−59 y sectional
Canada 423+505 F case-control Lower intake of dairy calcium in pregnant women with pre-eclampsia or Marcoux et al. 1991
26 y (mean) gestational hypertension than in pregnant controls.
Hawaii 3 150 M prospective, Non-drinkers of milk experienced stroke at twice the rate of milk consumers Abbott et al. 1996
(Honolulu Heart Program) 55−68 y 22-y follow-up (>500 ml milk/d).
Intake of non-dairy calcium was not related to thromboembolic stroke.
USA 43 738 M prospective, Intake of dairy calcium and total calcium intake were not associated Ascherio et al. 1998
(Health Professionals’ 40−75 y 8-y follow-up with stroke risk.
Follow-up Study)
USA 85 764 F prospective Calcium intake was inversely associated with risk of ischaemic stroke. Iso et al. 1999
(Nurses’ Health Study) 34−59 y 14-y follow-up Risk was increased if calcium intake <600 mg/d.
Inverse association was stronger for dairy than non-dairy calcium intake. 
SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure; M, male; F, female; y, years; NHANES, National Health and Nutrition Examination Survey
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between blood pressure and calcium intake from dairy sources (Sowers et al.
1985). In addition, a large Health Professionals’ Follow-up Study with more than
40 000 men failed to observe this association (Ascherio et al. 1998).
Some small clinical intervention studies have also investigated the effect of milk
or dairy products on blood pressure (Table 2). In a randomized cross-over study
with 50 normotensive participants, supplemental daily calcium intake      (1 150
mg) for eight weeks from different dairy products lowered SBP by
5 mmHg and DBP by 1 mmHg (Bierenbaum et al. 1988). In a double-blind
study with young healthy women (n=60) whose habitual calcium intake was low
(<500 mg/d), consumption of one litre of normal milk daily for six weeks lowered
SBP by 5 mmHg but did not significantly affect DBP (van Beresteijn et al. 1990).
In the same study, consumption of mineral-poor milk with one-tenth of calcium,
one-third of potassium and one-twentieth of magnesium of the normal milk
lowered SBP by 2.3 mmHg. This suggests that components other than minerals
in milk also have beneficial effects on blood pressure. In another open study
with 82 normotensive men and women, daily skim milk supplementation (1.14
litres) for eight weeks lowered SBP by 4.7 mmHg and DBP by 4.5 mmHg
(Buonopane et al. 1992). A recent double-blind cross-over study with
38 normotensive subjects found that replacing habitual consumption of any kind
of liquid milk with two servings of skim milk (on average an extra 184 ml of skim
milk daily) for four weeks reduced SBP by 3 mmHg (Hilary Green et al. 2000).
In a group receiving skim milk enriched with calcium, SBP decreased by
4 mmHg, whereas consumption of skim milk enriched with both calcium and
potassium decreased SBP by 8 mmHg (Hilary Green et al. 2000). However, all
studies have not demonstrated a beneficial effect of milk on blood pressure. For
example, in a randomized open trial with healthy middle-aged or elderly
participants (n=204), an increase in skim milk or 1% milk intake by 3 cups
(750 ml) per day had no effect on blood pressure (Barr et al. 2000).
More evidence on the advantageous effect of dairy products on blood pressure
is provided by the recent randomized intervention study Dietary Approaches to
Stop Hypertension (DASH), with almost 500 normotensive or mildly
TABLE 2. Intervention studies on consumption of dairy products and blood pressure.
Country Subjects Design Dietary intervention Results Reference
Age Duration
USA 162 M+F, HT+NT open ~1 litre calcium-fortified skim milk (1 400 mg calcium/d) SBP/DBP −4/−3 mmHg Bierenbaum et al. 1987
21−65 y 12 weeks In hypertensive individuals (n=27) SBP/DBP –9/−5 mmHg
USA 15 M+F, HT randomized 600 mg/d calcium supplementation as yoghurt  SBP −14 mmHg Zemel et al. 1988
diabetic adults parallel, open 600 mg/d calcium supplementation as calcium SBP  no effect
4 weeks carbonate
USA 50 M+F, NT randomized Yoghurt (~250 ml), cottage cheese (115 g), SBP −5 mmHg Bierenbaum et al. 1988
21−65 y cross-over and 1% milk (~500 ml) daily
open (supplemental dairy calcium intake 1 150 mg/d)
8 weeks Usual diet with orange juice instead of milk SBP  no effect
Netherlands 60 F, NT randomized Normal milk (1 litre/d) SBP −5 mmHg van Beresteijn et al. 1990
19−23 y double-blinded “Mineral-poor” milk (1 litre/d) SBP −2 mmHg
parallel
6 weeks Calcium intake from other foods <500 mg/d
USA 82 M+F, NT parallel, open ~1 litre skim milk/d SBP/DBP −5/−5 mmHg Buonopane et al. 1992
21−73 y 8 weeks Usual diet BP  no effect
USA 13 M, HT parallel, open Calcium intake from dairy 1 500 mg/d BP  no effect Kynast-Gales & Massey 1992
46−75 y 4 weeks Calcium intake from dairy 400 mg/d  BP  no effect
USA 38 M+F, NT randomized Skim milk (~500 ml/d) SBP −3 mmHg Hilary Green et al. 2000
Over 40 y cross-over High-calcium skim milk (~500 ml/d) SBP −4 mmHg
double-blinded High-calcium skim milk with potassium (~500 ml/d) SBP −8 mmHg
4 weeks
USA 204 M+F, NT randomized Increased skim or 1% milk consumption by 750 ml/d SBP/DBP −2/−1 mmHg Barr et al. 2000
55−85 y parallel, open Usual diet with milk consumption <375 ml/d SBP/DBP −3/−1 mmHg
12 weeks
SBP, systolic blood pressure; DBP, diastolic blood pressure; NT, normotensive; HT, hypertensive; M, male; F, female; y, years
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hypertensive subjects who did not take antihypertensive medication (Appel et al.
1997). In this study, consumption of a diet rich in fruits and vegetables for
8 weeks lowered SBP by 2.8 mmHg and DBP by 1.1 mmHg. When low-fat dairy
products were added to this diet (the combination diet), the blood pressure-
lowering effect was pronounced: SBP was lowered by 5.5 mmHg and DBP by
3.0 mmHg. Among hypertensive subjects, the reductions in SBP and DBP were
even greater (11.4 mmHg and 5.5 mmHg, respectively). Sodium content of the
diet was rather low (3 g/d), but no differences were present between the groups in
sodium content, body weight or alcohol consumption. The DASH II study showed
that the antihypertensive effect of the diet containing low-fat dairy products was
even stronger when sodium content was reduced to 1.5 g/d (Sacks et al. 2001).
In this study, SBP was lowered by 7.1 mmHg in normotensive subjects.
To summarize, data from the epidemiological and clinical studies show that dairy
products may have a positive effect on blood pressure and its complications (for
review, see Massey 2001). In general, the magnitude of the blood pressure-
lowering effect was 2−5 mmHg in SBP. The effect was stronger in hypertensive
than in normotensive subjects. Whether the beneficial effect of milk products is
related to calcium and other electrolytes or to some other components of milk has
not yet been fully elucidated, but some evidence exists that calcium is not the only
component of milk that has a favourable effect on blood pressure.
2.2 COMPONENTS OF MILK AND BLOOD PRESSURE
2.2.1 Calcium and blood pressure
The blood pressure-lowering effect associated with intake of milk and other dairy
products has often been attributed to calcium (Ackley et al. 1983; Bierenbaum et
al. 1988; van Beresteijn et al. 1990).
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In hypertensive animals, such as spontaneously hypertensive rats (SHR), dietary
calcium supplementation (1.5% calcium chloride) attenuates the development of
hypertension in young prehypertensive animals (Pörsti et al. 1990; Wuorela et al.
1992; Civantos et al. 1999). In addition, supplementary calcium lowers blood
pressure in adult SHR, whereas calcium deprivation results in increased blood
pressure in SHR (for review, see Schleiffer & Gairard 1995).
An inverse relationship between dietary calcium and blood pressure in humans
has been observed in several epidemiological studies (for reviews, see Geleijnse
& Grobbee 2000; Miller et al. 2000). A meta-analysis of observational studies on
dietary calcium intake estimated that an increase of 100 mg in daily calcium intake
would decrease SBP by 0.39 mmHg and DBP by 0.35 mmHg (Birkett 1998). In
some epidemiological studies, a reduced risk of hypertension has been associated
with dairy calcium but not with calcium from other sources (Abbott et al. 1996; Iso
et al. 1999).
The beneficial effect of calcium on blood pressure has also been demonstrated in
many intervention studies (for review, see Kotchen & McCarron 1998). A recent
meta-analysis of 42 randomized controlled trials with a total of 3 500 subjects
found that calcium supplementation (daily calcium intake >1 000 mg) for at least
two weeks leads to small reductions in both SBP (1.4 mmHg) and DBP
(0.8 mmHg) (Griffith et al. 1999). The reductions in SBP and DBP achieved with
dietary calcium were at least as great as those obtained with non-dietary calcium
supplementation (Griffith et al. 1999). Although the beneficial effect of increased
calcium intake has been observed in both normotensive and hypertensive
subjects, individuals with an increased risk of hypertension (e.g. African-
Americans, pregnant women) or with a low habitual intake of calcium are
suggested to be more likely to respond to an increased calcium intake with a
decrease in blood pressure than other individuals (for review, see Miller et al.
2000).
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2.2.2 Potassium and blood pressure
In addition to calcium, dairy products also contain other minerals, e.g.
potassium, which may have a beneficial effect on blood pressure (for review,
see Kotchen & McCarron 1998).
In SHR, the accelerated development of hypertension induced by a high-sodium
diet (3−8% NaCl) can be attenuated by an increased intake of potassium (8%
potassium chloride) (Sato et al. 1991; Ellis et al. 1992). However, when the
amount of sodium in the diet is moderate (0.4−0.7% NaCl), the advantageous
effect of potassium on the development of hypertension is not as evident. In
SHR without a sodium-load, potassium supplementation (1−8% potassium
chloride) has lowered blood pressure and reduced the development of
hypertension in some experimental settings (Wu et al. 1998; Jin et al. 1999), but
a beneficial effect has not been observed in all studies (Sato et al. 1991; Ellis et
al. 1992).
In the third cross-sectional National Health and Nutrition Examination Survey
(NHANES III) in the USA, with over 17 000 individuals aged 20 years or older,
SBP and DBP were negatively associated with potassium intake (Hajjar et al.
2001). The prospective Nurses’ Health Study found that low potassium intake
may contribute to an increased risk of ischaemic stroke (Iso et al. 1999). Data
from the American Health Professionals’ Follow-up Study suggests that an
increased intake of potassium may decrease the risk of stroke in middle-aged
and elderly American men (Ascherio et al. 1998).
A meta-analysis of 33 randomized controlled clinical trials with a total of 2 600
participants also provides evidence of the protective effect of potassium on blood
pressure (Whelton et al. 1997). SBP lowered by 3 mmHg and DBP by 2 mmHg
with a median daily potassium dosage of 2.9 g. In a study with 300 normotensive
women with low habitual intake of potassium (2.4 g/d), supplemental potassium
(1.6 g/d) had a modest blood pressure-lowering effect (2.0 mmHg in SBP and
1.7 mmHg in DBP) (Sacks et al. 1998). The blood pressure-lowering effect of
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potassium has been particularly apparent in hypertensive patients and in those
concurrently exposed to a high intake of sodium (for review, see Karppanen
1991). Thus, in the light of current knowledge, an increased intake of potassium
may be useful in the treatment of elevated blood pressure especially when sodium
intake is high.
2.2.3 Magnesium and blood pressure
Magnesium is another possible antihypertensive factor in milk. However, the
beneficial effect of magnesium on blood pressure is more controversial than that
of calcium and potassium (for review, see Kotchen & McCarron 1998).
In some experimental studies, magnesium supplementation (0.5−1% Mg) has
decreased blood pressure in mature SHR and inhibited the development
of hypertension in young SHR and in adult stroke-prone SHR (Wolf et al.
1987; Adachi et al. 1994). In addition, the accelerated development of
hypertension induced by high sodium intake (2.7% Na) in SHR can be
attenuated by concurrent supplemental potassium and magnesium (1.5%
and 0.1%, respectively) (Mervaala et al. 1992). However, a protective effect of
magnesium has not been found in all experimental studies (Overlack et al. 1987;
Evans et al. 1990; Mäkynen et al. 1995).
An overview of observational studies on dietary magnesium intake and blood
pressure suggests that increased magnesium is related to reduced blood
pressure (Mizushima et al. 1998). The cross-sectional Atherosclerosis Risk in
Communities (ARIC) study, with 15 000 middle-aged American participants,
found an inverse association between dietary magnesium intake and both SBP
and DBP (Ma et al. 1995). In addition, magnesium intake in the prospective
Nurses’ Health Study in the USA was related to a reduced risk of hypertension
development (Iso et al. 1999). In the NHANES III, however, magnesium was not
associated with any changes in blood pressure (Hajjar et al. 2001).
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The results from clinical intervention trials evaluating the effect of magnesium on
blood pressure have also been somewhat inconsistent (for review, see Saris et al.
2000). An overview of eight placebo-controlled studies detected no blood
pressure-lowering effect of magnesium supplementation (240−500 mg/d)
(Witteman & Grobbee 1990). More recently, in a randomized cross-over
intervention study, magnesium supplementation (486 mg/d) in middle-aged
hypertensive subjects (n=60) lowered SBP by 3.7 mmHg and DBP by 1.7 mmHg
(Kawano et al. 1998). In a study with 300 normotensive women, magnesium
supplementation (336 mg/d) had no effect on blood pressure (Sacks et al. 1998).
Taken together, magnesium may have an advantageous effect on blood pressure,
but thus far, epidemiological studies or intervention trials have produced no
convincing evidence.
2.2.4 Proteins and blood pressure
In addition to various minerals, milk is rich in protein. Milk proteins are divided into
caseins and whey proteins. Caseins, which comprise approximately 80% of total
protein content in bovine milk, are in turn divided into α-, β- and κ-caseins. Major
whey proteins, α-lactalbumin and β-lactoglobulin, account for 2−5% and 7−12% of
the total protein in bovine milk, respectively (Wong et al. 2000).
Some epidemiological studies suggest an inverse association between protein
intake and blood pressure (for reviews, see Obarzanek et al. 1996; He et al.
1999). Large cross-sectional studies, such as the Honolulu Heart Program with
6 000 subjects (Reed et al. 1985) and the Intersalt Study with 10 000 subjects
(Stamler et al. 1996a), found an inverse relationship between dietary protein
intake and both SBP and DBP. The Intersalt Study estimated that SBP and
DBP were on average 3.0 mmHg and 2.5 mmHg lower in persons with a high
dietary protein intake than in those whose intake was lower (81 vs. 44 g/d)
(Stamler et al. 1996a). In the prospective Nurses’ Health Study, the intake of
animal protein was inversely associated with the risk of haemorrhagic stroke
(Iso et al. 2001). Nevertheless, all epidemiological studies have not shown the
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beneficial relation between high intake of dietary protein and blood pressure. For
instance, the NHANES III found that a diet low in protein was associated with
reduced SBP (Hajjar et al. 2001).
A few intervention trials evaluating the effect of dietary proteins on blood pressure
have been performed (for review, see Obarzanek et al. 1996). Very recently, an
eight-week randomized controlled trial was performed in mildly hypertensive men
and women (n=36) aged at least 20 years, who received antihypertensive
medication (Burke et al. 2001). When compared to low-protein diet (12.5%
of energy), a diet supplemented with soy protein (protein intake 25% of energy)
lowered SBP by 5.9 mmHg and DBP by 2.6 mmHg (Burke et al. 2001). The
Multiple Risk Factor Intervention Trial (MRFIT) conducted in the USA with over
11 000 middle-aged men at high risk of coronary heart disease found that intake
of total protein was inversely associated with DBP (Stamler et al. 1996b). This
study was a randomized primary prevention trial in which diet counselling and
antihypertensive drug treatment were given to an intervention group to
reduce mortality in coronary heart disease. Some aspects in the other intervention
trials make interpretation of their results difficult (for review, see Obarzanek et
al. 1996). For example, most of the studies were conducted in normotensive
subjects, in whom a possible blood pressure-lowering effect might be difficult
to detect. Furthermore, none of the trials was specifically designed to test the
hypothesis that high protein intake lowers blood pressure. Moreover, sample
sizes were relatively small (n=13−69 per study) to allow detection of slight
changes in blood pressure. These clinical studies cannot, therefore, confirm the
inverse relation between dietary protein and blood pressure.
The underlying mechanism by which dietary proteins influence blood pressure is
unknown. One hypothesis is that proteins rich in specific amino acids may result in
high concentrations of these amino acids in specific brain regions or in blood
vessel walls, thus evoking a vasodepressor response (for review, see Obarzanek
et al. 1996). Tryptophan and glycine, for instance, have elicited a depressor
response in animals (for review, see Nurminen et al. 1998). Supplementation with
taurine has normalized blood pressure in experimental hypertension models, but it
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has not influenced blood pressure in normotensive rats (for review, see Niittynen
et al. 1999). Intravenous administration of arginine has reduced blood pressure in
hypertensive subjects, but oral administration has not induced any changes in
blood pressure in men with coronary artery disease, even though endothelial
function did improve (Niittynen et al. 1999). Another possibility is the fragmentation
of milk proteins into short-chain peptides, which may influence blood pressure.
2.2.5 Milk protein-derived peptides and blood pressure
Milk proteins are degraded into numerous peptide fragments by enzymatic
hydrolysis. These peptides have been described to possess a variety of
biochemical and physiological properties since 1979, when the first milk peptides
with an opioid-like activity were discovered (Brantl et al. 1979; Henschen et al.
1979; Zioudrou et al. 1979). Other properties of milk protein-derived peptides
include angiotensin-converting enzyme (ACE) inhibitory activity as well as mineral
binding, antithrombotic, antimicrobial and immunomodulatory properties (Table 3)
(for reviews, see FitzGerald & Meisel 2000; Gill et al. 2000; van Hooijdonk et al.
2000; Rutherfurd & Gill 2000; Vegarud et al. 2000).
The cardiovascular effects of milk protein-derived peptides have not been
extensively studied to date, but along with other components of milk, they appear
to have beneficial effects on blood pressure (for reviews, see Groziak & Miller
2000; Pfeuffer & Schrezenmeir 2000).
TABLE 3. Selected bovine milk protein-derived peptides and their properties.
Property Peptide (amino acids) Source Effects Reference
OPIOID-LIKE β-Casomorphin-7 β-Casein (f60−66) Inhibits contraction in guinea pig ileum assay and Brantl et al. 1979;
ACTIVITY (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) in mouse vas deferens assay Henschen et al. 1979
αs1-Exorphin αs1-Casein (f90−95) Inhibits stimulated mouse vas deferens, Loukas et al. 1983
(Arg-Tyr-Leu-Gly-Tyr-Leu) binds to opioid receptors in radioreceptor assay
α-Lactorphin α-Lactalbumin (f50−53) Inhibits contraction in guinea pig ileum assay, Yoshikawa et al. 1986;
(Tyr-Gly-Leu-Phe) binds to opioid receptors in radioreceptor assay Antila et al. 1991
β-Lactorphin β-Lactoglobulin (f102−105) Inhibits/stimulates contraction in guinea pig ileum Yoshikawa et al. 1986;
(Tyr-Leu-Leu-Phe) assay, binds to opioid receptor in radioreceptor assay Antila et al. 1991
ACE IPP β-Casein (f74−76) Inhibits ACE in spectrophotometric assay Nakamura et al. 1995a
INHIBITION (Ile-Pro-Pro) κ-Casein (f108−110)
VPP β-Casein (f84−86) Inhibits ACE in spectrophotometric assay Nakamura et al. 1995a
(Val-Pro-Pro) 
α-Lactorphin α-Lactalbumin (f50−53) Inhibits ACE in spectrophotometric assay Mullally et al. 1996
β-Lactorphin β-Lactoglobulin (f102−105) Inhibits ACE in spectrophotometric assay Mullally et al. 1996
MINERAL-BINDING Caseinophosphopeptides αs1-Casein (f59−79), Increases solubility of calcium, Berrocal et al. 1989;
PROPERTY (- Ser(P)-Ser(P)-Ser(P)- αs2-Casein (f46−70), enhances absorption of calcium Gagnaire et al. 1996
Glu-Glu -) β-Casein (f33−48)
ANTITHROMBOTIC Casoplatelin κ-Casein (f106−116) Inhibits aggregation of ADP-activated platelets and Jollés et al. 1986
EFFECT (Met-Ala-Ile-Pro-Pro-Lys-Lys- binding of fibrinogen γ-chain to receptor at platelet
Asn-Gln-Asp-Lys) surface
ANTIMICROBIAL Casocidin-1 αs2-Casein (f165−203) Inhibits growth of E. coli and Staphylococcus carnosus Zucht et al. 1995
ACTIVITY
IMMUNO- Tyr-Gly α-Lactalbumin (f50−51) Enhances proliferation of human peripheral Kayser & Meisel 1996
MODULATORY blood lymphocytes
ACTIVITY Thr-Thr-Met-Pro-Leu-Trp αs1-Casein (f194−199) Stimulate phagocytosis of sheep red blood  Migliore-Samour et al. 1989
cells by murine peritoneal macrophages
Pro-Gly-Pro-Ile-Pro-Asn, β-Casein (f63−68), in vitro
Leu-Leu-Tyr (f191−193)
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Several milk casein-derived peptides are able to lower blood pressure (Table
4). Various peptides that consist of 6−12 amino acid residues have been
reported to possess antihypertensive effects in SHR after a single oral
administration (Karaki et al. 1990; Fujita et al. 1996; Maeno et al. 1996).
Likewise, isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) have
dose-dependently lowered blood pressure after a single oral administration in
SHR (Nakamura et al. 1995b). The effect of the tripeptides lasted for eight
hours. No effect on blood pressure was observed in normotensive WKY
(Nakamura et al. 1995b). Milk whey protein-derived peptides have also been
shown to influence blood pressure. A small dipeptide Tyr-Pro isolated from the
whey of a yoghurt-like fermented product lowered SBP in SHR for eight hours
after a single oral administration (Yamamoto et al. 1999).
An acute antihypertensive effect in SHR has also been observed after a single
oral administration of a sour milk product containing the tripeptides IPP and
VPP (Calpis®) (Nakamura et al. 1995b). In addition, long-term feeding of SHR
with a diet enriched with Calpis® -powder has attenuated development of
hypertension in young prehypertensive SHR (Nakamura et al. 1996).
The design of some of the studies investigating the acute effects of milk
protein-derived peptides does, however, raise questions. The number of rats
has sometimes been quite small (n=3) (Karaki et al. 1990; Abubakar et al.
1999). Another problem is that the baseline SBP level has not always been
reported for the peptide groups and the control group separately (Nakamura et
al. 1995b; Fujita et al. 1996; Maeno et al. 1996; Yamamoto et al. 1999). Thus,
interpretation of these results is somewhat difficult.
In humans, the antihypertensive effect of milk protein-derived peptides has yet
to be demonstrated. However, some studies have investigated the effect of
fermented milk products containing IPP and VPP on blood pressure. In a small
controlled randomized clinical trial, daily intake of a fermented milk product
(Calpis®) for eight weeks (95 ml/d) lowered blood pressure in mildly
hypertensive patients (n=30) (Hata et al. 1996). Most of the patients were taking
Table 4. ACE inhibitory activity of selected milk protein-derived antihypertensive peptides.
Peptide Antihypertensive Maximal decrease ACE-inhibition Reference
oral dose in SHR in SBP, mean±SEM (IC50)*
Phe-Phe-Val-Ala-Pro-Phe- 100 mg/kg 34±13 mmHg 59 µM Karaki et al. 1990
Pro-Glu-Val-Phe-Gly-Lys (72 µmol/kg) (n=3)
Ala-Val-Pro-Tyr-Pro-Gln-Arg 100 mg/kg 10±1 mmHg 15 µM Karaki et al. 1990
(121 µmol/kg) (n=3)
Thr-Thr-Met-Pro-Leu-Trp 100 mg/kg 14±4 mmHg 16 µM Karaki et al. 1990
(134 µmol/kg) (n=3)
Ile-Pro-Pro 5 mg/kg 18±4 mmHg 5 µM Nakamura et al. 1995b
(15 µmol/kg) (n=4-6)
Val-Pro-Pro 5 mg/kg 20±2 mmHg 9 µM Nakamura et al. 1995b
(16 µmol/kg) (n=4-6)
Lys-Val-Leu-Pro-Val-Pro-Gln 2 mg/kg 32±6 mmHg 1000 µM Maeno et al. 1996
(3 µmol/kg) (n=5)
Lys-Val-Leu-Pro-Val-Pro 1 mg/kg 32±1 mmHg 5 µM Maeno et al. 1996
(1.5 µmol/kg) (n=?)
Tyr-Pro-Phe-Pro-Pro-Leu 10 mg/kg 24±? mmHg ? Fujita et al. 1996
(14 µmol/kg) (n=5)
Ile-Pro-Ala 8 mg/kg 31±? mmHg 141 µM Abubakar et al. 1999
(24 µmol/kg) (n=3)
Tyr-Pro 10 mg/kg 32±7 mmHg 720 µM Yamamoto et al. 1999
(36 µmol/kg) (n=5)
*IC50, Inhibitory concentration 50%, the concentration at which 50% of enzyme activity is inhibited; ACE, angiotensin-converting enzyme; SHR, spontaneously hypertensive rat;
SBP, systolic blood pressure; n, number of animals; ?, not reported
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antihypertensive medication. As compared with baseline (156/89 mmHg), SBP
decreased by 14 mmHg and DBP by 7 mmHg. In another clinical pilot study, an
eight-week intake of a different sour milk product (150 ml/d) lowered SBP and
DBP in mildly hypertensive patients (n=17) (baseline blood pressure
148/94 mmHg) (Seppo et al. 2002). These patients were not taking
antihypertensive medication. In addition, one small clinical study has
investigated the effect of fermented milk supplemented with whey protein
concentrate on blood pressure in healthy normotensive men (n=20) (Kawase et
al. 2000). SBP was reported to be slightly lowered in the group receiving the
fermented milk for eight weeks (400 ml/d) as compared with that group
receiving a skim milk-based control fluid.
The biologically active peptide fragments may be released from milk proteins in
enzymatic proteolysis by digestive enzymes in the gastrointestinal tract. In vitro,
enzymes such as trypsin, pepsin and chymotrypsin have been used to release
peptides from their parent proteins (Meisel & Bockelmann 1999). Biologically
active peptides are also generated during milk fermentation by enzymes
produced by various lactic acid bacteria, e.g. Lactobacillus helveticus,
Lactococcus lactis subsp. cremoris FT4 and Lactobacillus delbrueckii
subspecies bulgaricus SS1 (Nakamura et al. 1995a; Gobbetti et al. 2000). Once
liberated from proteins, these peptides may influence different physiological
functions.
2.3 POSSIBLE MECHANISMS BY WHICH MILK PROTEIN-DERIVED
PEPTIDES INFLUENCE BLOOD PRESSURE
2.3.1 ACE inhibitory activity
The most often studied mechanism underlying the blood pressure-lowering
effect of milk protein-derived peptides is inhibition of the activity of ACE
(Yamamoto 1997; Takano 1998). Inhibition of the renin-angiotensin system with
ACE inhibitors or with angiotensin receptor antagonists is an effective means to
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lower elevated blood pressure in hypertensive patients (for review, see
Fyhrquist et al. 1995) or prevent the development of genetic hypertension in
SHR (Freslon & Giudicelli 1983; Richer et al. 1991).
ACE is an enzyme, which catalyses the conversion of decapeptide angiotensin I
into octapeptide angiotensin II, the effector compound of the renin-angiotensin
system (for review, see Brown & Vaughan 1998). Angiotensin II has a central
role in the regulation of blood pressure and vascular structure. Reducing the
levels of angiotensin II by ACE inhibition results in decreased vasoconstriction,
a decrease in blood pressure as well as diminished sympathetic activity and
aldosterone secretion (for review, see Fyhrquist et al. 1995).
ACE is identical to kininase II, an enzyme that rapidly inactivates bradykinin.
Bradykinin is a nonapeptide that also participates in blood pressure regulation.
Increased bradykinin levels following ACE inhibition lead to indirect
vasodilatation by increased production of nitric oxide (NO), prostacyclin and
endothelium-derived hyperpolarizing factor (EDHF) in vascular endothelium (for
review, see Mombouli & Vanhoutte 1995). Thus, the increased availability of
bradykinin due to ACE inhibition may be partly responsible for the
advantageous effects of ACE inhibitors on blood pressure (for review, see
Mombouli & Vanhoutte 1995).
The importance of the renin-angiotensin system in blood pressure regulation is
indisputable. In addition to the well-established circulating renin-angiotensin
system, components of the system are localized in several tissues, e.g. the
heart, vascular wall, kidney, adrenal gland and brain (for review, see Stroth &
Unger 1999).
Several milk protein-derived peptides have been shown to inhibit the activity of
ACE (Table 4) (for review, see FitzGerald & Meisel 2000). The most potent
ACE inhibitory activities have been measured for tripeptides IPP and VPP,
which have also been reported to lower blood pressure in SHR (Nakamura et
al. 1995b). The potency of the ACE inhibitory effect of milk protein-derived
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peptides, such as IPP and VPP is, however, considerably lower than that
reported for ACE inhibitory drugs. For instance, IC50 for captopril is within the
nanomolar range (Wyvratt & Patchett 1985), whereas the IC50 values for IPP
and VPP are one thousand-fold higher (Table 4). Therefore, the blood
pressure-lowering effect of the milk peptides does not correlate with the ACE
inhibitory activity, and other mechanisms by which they lower blood pressure
seem likely.
2.3.2 Opioid-like activity
Several milk protein-derived peptides that possess opioid-like activities have
been identified (for reviews, see Teschemacher et al. 1997; Meisel & FitzGerald
2000). Opioids are substances that elicit effects similar to morphine, such as
sedation and antinociception. The effects of opioids are mainly mediated
through opioid receptors (µ, δ, κ) in the central nervous system. Opioid
receptors have also been found in peripheral tissues related to cardiovascular
regulation, including the vascular endothelium (Cadet et al. 2000), vascular
smooth muscle (Saeed et al. 2000), sympathetic nerves (Hughes et al. 1977)
and adrenal glands (Viveros et al. 1979). In fact, endogenous opioid peptides,
such as endorphins and enkephalins, may be involved in blood pressure
regulation (for review, see Sirén & Feuerstein 1992). The endogenous opioid
system has been suggested to play an adaptive role in cardiovascular control
during stress situations (for review, see Sirén & Feuerstein 1992). Endogenous
opioids have further been proposed to have a role in the pathogenesis of
hypertension in SHR (Levin et al. 1986). Difference in the sensitivity to
endogenous opioid peptides has been demonstrated between SHR and WKY
(Wong & Ingenito 1995; Tsuda et al. 2000). In patients with essential
hypertension, plasma β-endorphin levels are higher than in normotensive
subjects (Guasti et al. 1996; Saadjian et al. 2000), although reduced plasma
levels of β-endorphin and leu-enkephalin have also been reported in the former
group (Zheng et al. 1995). Thus, endogenous opioids may be involved in the
pathogenesis of hypertension.
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β-Endorphin lowers blood pressure in conscious and anaesthetized rats after
peripheral or central administration (Bolme et al. 1978; Lemaire et al. 1978;
Petty et al. 1982; Sitsen et al. 1982; Levin et al. 1986; Unal et al. 1997). The
cardiovascular effects of enkephalins (leu-enkephalin, met-enkephalin) seem to
be strongly influenced by anaesthesia. In conscious animals, centrally or
peripherally administered enkephalins have raised blood pressure (Schaz et al.
1980; Sander et al. 1982). In contrast, a depressor response has most often
been observed in anaesthetized animals (Schaz et al. 1980; Sander et al. 1982;
Clark et al. 1988; Rhee & Park 1995). In some studies, however, the effect of
met-enkephalin on blood pressure has been negligible, regardless of
anaesthesia (Laubie et al. 1977; Bellett et al. 1980). Newly discovered
endogenous opioid peptides, endomorphins (Zadina et al. 1997), have also
decreased systemic arterial pressure in anaesthetized rats after peripheral
administration (Champion et al. 1997). However, the effect of these peptides on
blood pressure in conscious animals remains unclear.
As mentioned above, several milk protein-derived peptides that elicit opioid-like
activities have been found (Table 5) (for reviews, see Teschemacher et al.
1997; Meisel & FitzGerald 2000). Agonistic properties have been demonstrated
in radioreceptor studies and in isolated organ preparations such as guinea pig
ileum and mouse vas deferens (Chiba & Yoshikawa 1986). Milk caseins are the
usual sources of peptides with opioid-like properties. The opioid peptides
derived from α-casein are named α-exorphins, whereas the opioid peptides
originating from β-caseins are called β-casomorphins. Peptides that originate
from κ-casein are called casoxins. In addition, whey proteins, e.g. α-lactalbumin
and β-lactoglobulin, contain sequences of opioid peptides in their primary
structures (for reviews, see Teschemacher et al. 1997; Meisel & FitzGerald
2000).
α-Lactorphin is a tetrapeptide (Tyr-Gly-Leu-Phe) found in the primary structure
of bovine milk whey protein α-lactalbumin (f50−53). β-Lactorphin (Tyr-Leu-Leu-
Phe) originates from another whey protein, β-lactoglobulin (f102−105). These
tetrapeptides are released from the milk proteins by enzymatic digestion with
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TABLE 5. Endogenous opioid peptides and milk protein-derived peptides with
opioid-like activity.
Peptide Amino acid sequence Precursor/
Source
Leu-enkephalin Tyr-Gly-Gly-Phe-Leu Proenkephalin A
Met-enkephalin Tyr-Gly-Gly-Phe-Met Proenkephalin A
β-Endorphin Tyr-Gly-Gly-Phe-Met-Thr-Ser- Proopiomelanocortin
Glu-Lys-Ser-Gln-Thr-Pro-Leu-
Ile-Ile-Lys-Asn-Val-His-Lys-Gly-Gln
Dynorphin A Tyr-Gly-Gly-Phe-Leu-Arg-Arg- Prodynorphin
Ile-Arg-Pro-Lys-Leu-Lys-Trp-
Asp-Asn-Gln-OH
Nociceptin/ H2N-Phe-Gly-Gly-Phe-Thr-Gly- Pronociceptin
Orphanin FQ Ala-Arg-Lys-Ser-Ala-Arg-Lys-
Leu-Ala-Asn-Gln-COOH
Endomorphin 1 Tyr-Pro-Trp-Phe-NH2 unknown
Endomorphin 2 Tyr-Pro-Phe-Phe-NH2 unknown
β-Casomorphin-11 Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro- β-Casein
Asn-Ser-Leu
β-Casomorphin-7 Tyr-Pro-Phe-Pro-Gly-Pro-Ile β-Casein
β-Casomorphin-5 Tyr-Pro-Phe-Pro-Gly β-Casein
β-Casomorphin-4 Tyr-Pro-Phe-Pro β-Casein
αs1-Exorphin Arg-Tyr-Leu-Gly-Tyr-Leu-Glu αs1-Casein
αs1-Exorphin Arg-Tyr-Leu-Gly-Tyr-Leu αs1-Casein
Casoxin A Tyr-Pro-Ser-Tyr-Gly-Leu-Asn-Tyr κ-Casein
Casoxin B Tyr-Pro-Tyr-Tyr κ-Casein
Casoxin C Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg κ-Casein
Casoxin D Tyr-Val-Pro-Phe-Pro-Pro-Phe αs1-Casein
α-Lactorphin Tyr-Gly-Leu-Phe α-Lactalbumin
β-Lactorphin Tyr-Leu-Leu-Phe β-Lactoglobulin
pepsin and trypsin (Antila et al. 1991). They bind to opioid receptors at
micromolar concentrations in vitro (Yoshikawa et al. 1986; Antila et al. 1991). In
addition, the structures of α-lactorphin and β-lactorphin closely resemble the N-
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terminal amino acid residues of many endogenous opioid peptides which share
a tetrapeptide sequence Tyr-Gly-Gly-Phe- at their N-termini (Table 5) (for
review, see Dhawan et al. 1996).
In summary, the involvement of the opioid system in cardiovascular regulation
is complex due to the existence of numerous endogenous opioid peptides and
multiple opioid receptors. Moreover, variation in species, anaesthesia, route of
administration, stressed vs. resting animals, etc., have produced contradictory
results in studies attempting to clarify the role of endogenous opioids in
cardiovascular regulation. Nevertheless, increasing amount of evidence
suggests that both endogenous and exogenous opioid receptor ligands may
affect blood pressure.
2.3.3 Influence on arterial tone
Milk protein-derived peptides may also influence blood pressure by affecting
arterial tone. The arterial tone is maintained by vascular endothelium, which
lines all blood vessels. The vascular endothelium responds to various physical,
chemical and hormonal signals and to haemodynamic changes by releasing
vasorelaxing substances, such as nitric oxide (NO), prostacyclin and
endothelium-derived hyperpolarizing factor (EDHF), and vasoconstricting
factors like angiotensin II and endothelin-1 (for review, see Aleixandre & Lopez-
Miranda 1999; Mombouli & Vanhoutte 1999) (Figure 1).
NO is constantly released in small amounts by the endothelial cells, e.g. in
response to shear stress, acetylcholine (ACh) and bradykinin (for reviews, see
Marín & Rodríguez-Martínez 1997; Vallance & Chan 2001). In the endothelium,
NO is synthesized from L-arginine by the constitutive endothelial NO synthase
(NOS) isoenzyme. Endothelial NOS, like the other NOS isoenzymes (neuronal
and inducible NOS), is competitively inhibited by L-arginine analogues such as
NG-nitro-L-arginine methyl ester (L-NAME) (for review, see Hobbs et al. 1999).
Release of NO causes vasodilation by activating soluble guanylate cyclase,
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Figure 1. Endothelium-derived vasoconstricting and vasorelaxing factors
(modified from Mombouli & Vanhoutte 1999).
Angiotensin II and endothelin-1 stimulate phospholipase C, leading to inositol triphosphate
(IP3) -production and release of intracellular calcium, and to contraction of vascular smooth muscle.
Depolarization, on the other hand, causes vasoconstriction by increasing calcium influx into the cell.
Acetylcholine, bradykinin and shear stress stimulate endothelial nitric oxide (NO) synthase to produce NO,
which then diffuses into smooth muscle cells and causes vasodilation via increased production of cyclic
guanosine monophosphate (cGMP). They also stimulate the production of endothelium-derived
hyperpolarizing factor (EDHF), which induces hyperpolarization of the smooth muscle membrane and
thereby inhibits calcium influx. Endothelial cyclooxygenase produces prostacyclin (PGI2), relaxing vascular
smooth muscle via increased production of cyclic adenosine monophosphate (cAMP). AA, arachidonic
acid; ACE, angiotensin-converting enzyme; ATP, adenosine triphosphate; ECE, endothelin-converting
enzyme; GTP, guanosine triphosphate; PI, phosphoinositol.
which produces the intracellular messenger, cyclic guanosine monophosphate
(cGMP) (for review, see Marín & Rodríguez-Martínez 1997). Endothelium-
derived NO contributes to the overall regulation of arterial blood pressure by
relaxing vascular smooth muscle.
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Prostanoids are produced from arachidonic acid by cyclooxygenase (COX)
isoforms 1 and 2. The majority of tissues constitutively express COX-1,
whereas inducible COX-2 is expressed mainly after inflammatory or mitogenic
stimuli. COX isoenzymes are inhibited by COX inhibitors such as non-steroidal
anti-inflammatory drugs (for review, see Vane et al. 1998). Prostacyclin is a
vasodilatory prostanoid that is produced in endothelial cells. Endothelium also
produces other vasodilatory prostanoids, e.g. prostaglandin E2. In addition,
endothelial COX produces vasoconstrictive prostanoids such as prostaglandin
F2α, prostaglandin H2 or thromboxane A2. Under normal circumstances,
however, the influence of the small amounts of vasoconstrictor prostanoids
released by endothelial cells is masked by the production of prostacyclin and
other endothelium-derived vasodilatory substances (for review, see Mombouli &
Vanhoutte 1999).
The endothelium-dependent relaxation of the vascular wall cannot be fully
explained by the release of NO and prostacyclin since a degree of a relaxation
can be achieved in the presence of inhibitors of NOS and COX (for review, see
Félétou & Vanhoutte 1999). The additional relaxing factor EDHF causes
smooth muscle relaxation by increasing the membrane potential of muscle
cells. Hyperpolarization then inhibits calcium entry into the cell via calcium
channels. While the nature of EDHF remains obscure, it seems to activate
calcium-activated potassium channels in vascular smooth muscle cells (Oltman
et al. 1998; Fisslthaler et al. 1999). Possible candidates for EDHF include
metabolites of arachidonic acid, such as epoxyeicosatrienoic acids, and their
dihydroxy-eicosatrienoic acid metabolites (Campbell et al. 1996; Oltman et al.
1998; Fisslthaler et al. 1999), K+ itself (Edwards et al. 1998) or the electrical
couplings via gap junctions (Brandes et al. 2000). Induction of a specific
endothelial cytochrome P450 isoenzyme has enhanced the formation of certain
epoxy-eicosatrienoic acids as well as EDHF-mediated hyperpolarization and
relaxation, and has thus been proposed to act as an EDHF synthase
(Fisslthaler et al. 1999).
33
Endothelial dysfunction is a common finding in experimental models of genetic
hypertension and in human essential hypertension (for reviews, see Harrison
1997; Aleixandre & Lopez-Miranda 1999). The dysfunction may be defined as
an imbalance between the synthesis, release and effect of factors synthesized
by the endothelial cells that relax or contract the vascular smooth muscle (for
reviews, see Harrison 1997; Aleixandre & Lopez-Miranda 1999). Endothelial
dysfunction is often associated with impaired function of the NO pathway (for
reviews, see Harrison 1997; Marín & Rodríguez-Martinez 1997; Boulanger
1999). Whether the reduction in endothelium-dependent vasodilation is due to
reduced release, enhanced breakdown or reduced response to NO is unclear.
In any case, treatments that increase NO bioavailability may restore endothelial
function and have beneficial effects on blood pressure and hypertension-related
vascular injury (for review, see Vallance & Chan 2001). In contrast, inhibition of
NO synthesis with NOS inhibitors, such as L-NAME, diminishes endothelium-
dependent relaxation of isolated arteries, decreases blood flow in vivo and
induces pronounced and sustained hypertension (for review, see Vapaatalo et
al. 2000). In addition, release of vasoconstrictory prostanoids
 
has been
proposed to be increased in endothelial dysfunction in SHR (Matrougui et al.
1997; Kagota et al. 1999; Zhou et al. 1999). Moreover, inhibition of COX
normalizes endothelial dysfunction in patients with essential hypertension and
in SHR (Takase et al. 1994; Taddei et al. 1997). The endothelium-dependent
hyperpolarization mediated by EDHF is also suggested to be impaired in SHR
(Fujii et al. 1992).
Functions other than vasodilation may also be affected in endothelial
dysfunction. For instance, the expression of adhesion molecules that can
interact with platelets and leucocytes is increased in damaged endothelial
cells. Likewise, the propensity of vascular smooth muscle cells to proliferate
or migrate becomes enhanced due to increased release of growth
promoters from the dysfunctional endothelial cells (for review, see Haller 1997).
In addition to endothelium-derived substances, various other factors, including
endogenous opioid peptides, can influence arterial tone. Endomorphins and
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met-enkephalin have been shown to possess vasodilatory activity, which has
been attenuated by L-NAME (Champion & Kadowitz 1998; Hugghins et al.
2000). The presence of opioid receptors in the endothelium has also been
demonstrated (Cadet et al. 2000). Consequently, opioid receptor stimulation in
the vascular endothelium has been proposed to release NO (Stefano et al.
1995, 1998).
Some milk-derived peptides have been shown to have vasodilatory effects in
vitro. Casomokinin L (Tyr-Pro-Phe-Pro-Pro-Leu), a derivative of α-casein-
derived peptide casoxin D (Tyr-Val-Phe-Pro-Pro-Phe), relaxed canine
mesenteric arteries (Fujita et al. 1996). The effect was NO-dependent since the
relaxation induced by casomokinin L was partly inhibited by L-NAME. The
relaxation induced by casoxin D was not inhibited by the NO synthase inhibitor
but by the COX inhibitor indomethacin, suggesting that vasodilatory prostanoids
were involved in the action of this peptide (Yoshikawa et al. 1994). Vasodilatory
peptides have also been identified in foods other than milk. An ovalbumin-
derived hexapeptide (Arg-Ala-Asp-His-Pro-Phe) exerts a dose-related and NO-
dependent vasodilation in mesenteric arterial preparations of SHR (Matoba et
al. 1999). A single oral administration of this peptide has lowered SBP in adult
SHR (Matoba et al. 1999). In addition, peptic digests of certain food proteins
have inhibited ECE activity in vitro (Okitsu et al. 1995).
2.3.4 Mineral binding properties
Another mechanism by which milk protein-derived peptides may influence
blood pressure is by enhancing calcium absorption via casein-derived
phosphopeptides (for review, see Scholz-Ahrens & Schrezenmeir 2000;
Vegarud et al. 2000). These peptides may also affect the absorption of other
minerals, e.g. iron and zinc. Although there is evidence of improved calcium
absorption by casein-derived phosphopeptides in vitro (Kitts et al. 1992; Yuan &
Kitts 1994), in vivo studies have produced conflicting results. Calcium
absorption in rats has been enhanced in some studies following the addition of
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casein phosphopeptides to the diet (Hansen et al. 1996; Tsuchita et al. 2001),
whereas other studies have not detected any improvement (Brommage et al.
1991; Kopra et al. 1992; Bennett et al. 2000). As mentioned previously, the
advantageous effect of dietary calcium on blood pressure in humans has been
observed in several epidemiological and intervention studies (for reviews, see
Geleijnse & Grobbee 2000; Miller et al. 2000). Casein-derived phosphopeptides
may therefore indirectly influence blood pressure by increasing calcium
absorption.
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3 AIMS OF THE STUDY
Epidemiological and clinical data imply that milk and milk products have
beneficial effects on blood pressure. The effect may be due to calcium or other
electrolytes in milk. During recent years, however, experimental studies have
shown that various milk protein-derived peptides possess antihypertensive
properties. The present study investigated the effects of various milk products
and milk protein-derived peptides on blood pressure, development of
hypertension, and arterial function using SHR as the experimental model of
hypertension.
The specific aims of the study were:
• To investigate the acute effects of milk protein-derived peptides α-
lactorphin and β-lactorphin on blood pressure in hypertensive SHR and
normotensive WKY.
• To investigate the role of opioid mechanisms and ACE inhibitory activity in
the antihypertensive effect of α-lactorphin in SHR.
• To examine the effects of α-lactorphin and β-lactorphin on arterial function
in vitro and to evaluate the importance of various endothelium-derived
factors (NO, prostanoids, EDHF) in the vascular actions of the peptides.
• To evaluate the effect of long-term intake of milk peptides IPP and VPP,
and various milk products containing these tripeptides on the development
of hypertension in young prehypertensive SHR.
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4 MATERIALS AND METHODS
4.1 EXPERIMENTAL ANIMALS
SHR, WKY and Wistar rats were used in the studies as presented in Table 6.
The rats were purchased from Harlan Ltd, UK, Harlan Ltd, IN, USA, or
Laboratory Animal Centre, University of Helsinki, Finland. Rats were housed 4-
5 to a cage in a standard experimental animal laboratory (illuminated from 6
a.m. to 6 p.m., room temperature 22–24°C, relative humidity 40±5%) and had
free access to food pellets (R36, Lactamin, Stockholm, Sweden) and drinking
fluid. During the radiotelemetry experiments the animals were housed
individually after the implantation of a telemetric device.
The study protocols were approved by the Animal Experimentation Committee
of the Institute of Biomedicine, University of Helsinki, or by the Provincial State
Office of Southern Finland.
TABLE 6. Experimental animals
Experiment Strain Number Gender Age
Weight
Acute experiments SHR 28 Male 18−26 weeks
(Study I and WKY 9 250−490 g
unpublished data)
Long-term experiments SHR 129 Male 6−8 weeks
(Studies III, IV and 120−180 g
unpublished data) at baseline
Studies on SHR 27 Male 30−35 weeks
arterial function WKY 10
(Study II)
Functional bioassay Wistar 18 Female 220−240 g
of ACE inhibitory
activity
(Study IV)
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4.2 TREATMENTS
4.2.1 Acute experiments (Study I, unpublished data)
In the acute experiments, adult SHR received subcutaneous (s.c.) injections of
saline or α-lactorphin (Tyr-Gly-Leu-Phe) (1 µg/kg−1 mg/kg) or β-lactorphin
(Tyr-Leu-Leu-Phe) (1−100 µg/kg). α-Lactorphin was also given to WKY
(100 µg/kg−1 mg/kg s.c.). In addition, constituent amino acids of the peptides
were given to SHR at the doses that could maximally be released from
α-lactorphin or β-lactorphin after 100 µg/kg (L-tyrosine 35 µg/kg, L-glycine
15 µg/kg, L-leucine 25 µg/kg, L-phenylalanine 30 µg/kg s.c.). Captopril
(1 µg/kg−10 mg/kg s.c.) was also given to SHR.
Pretreatment with an opioid receptor antagonist naloxone (0.3, 1 and 3 mg/kg
s.c.), a bradykinin B2-receptor antagonist HOE140 (250 µg/kg s.c.) or saline
(1 ml/kg s.c.) were given to SHR 30 min before the administration of
α-lactorphin (100 µg/kg s.c.). Doses of naloxone and HOE140 were selected on
the basis of previous studies. Naloxone (1 mg/kg s.c.) has been shown to
antagonize the antinociceptive effect of morphine at 30 min in rats (Kontinen &
Kalso 1995). HOE140 has been demonstrated to inhibit the depressor response
to exogenous bradykinin at a comparable dose as that used in the present
study (Berkenboom et al. 1995).
4.2.2 Long-term experiments (Studies III, IV, unpublished data)
Blood pressure- and body weight-matched young prehypertensive SHR
(6−8 weeks) were divided into groups (n=8−11 per group) to receive different
drinking fluids ad libitum for 12−14 weeks:
39
Study III:
1) A control group receiving tap water
2) A group receiving skim milk (Valio Ltd, Helsinki, Finland)
3) A group receiving the whey of fermented milk A containing 14−16 mg/l IPP
and 20−26 mg/l VPP (Valio Ltd, R&D, Helsinki, Finland)
4) A group receiving fermented milk B containing 6−8 mg/l IPP and 10−12
mg/l VPP (Calpis®).
Study IV:
1) A control group receiving tap water
2) A group receiving IPP and VPP dissolved in tap water
3) A group receiving a sour milk product containing 16−18 mg/l IPP and
16−18 mg/l VPP (Valio Ltd, R&D, Helsinki, Finland). This product is referred
to as fermented milk C.
In addition, the effect of long-term oral intake of α-lactalbumin or a peptic
hydrolysate of α-lactalbumin on the development of hypertension was
investigated in young prehypertensive SHR (unpublished data). The doses of
α-lactalbumin or peptic hydrolysate of α-lactalbumin (255 mg/kg) were chosen
to contain the amount of α-lactorphin that lowered blood pressure in adult SHR
(100 µg/kg s.c.). The oral bioavailability was estimated to be 1%. The
calculations were based on theoretical release of 39 mg of α-lactorphin from
1 g of α-lactalbumin (Meisel 1998).
4.3 MEASUREMENT OF BLOOD PRESSURE
4.3.1 Radiotelemetry (Study I, unpublished data)
For the direct radiotelemetric registration of blood pressure and heart rate, data
were collected with a computer-driven data acquisition system (Data Sciences
Inc, MN, USA). Baseline cardiovascular parameters were measured for one
hour before the injections in the acute experiments and for three days before
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the beginning of the treatment period in the long-term experiment. For
implantation of the telemetric transmitter devices, the rats were anaesthetised
with fentanyl-fluanisone (0.5 ml/kg intraperitoneally (i.p). solution containing
fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml) and midazolam
(0.5 mg/kg i.p.). The tip of the catheter connected to the transmitter was
inserted into the abdominal aorta below the renal artery, and the transmitter
was fixed to the abdominal wall. After the operation, buprenorphin (0.1 mg/kg
s.c.) was given to relieve pain for 3 days. Ampicillin (1 g/kg i.p.) was given
during the surgical procedure and 2 days afterwards. The rats were allowed
post-operative recovery of at least one week before the experiments.
4.3.2 Tail-cuff method (Studies III, IV)
In the long-term experiments investigating the effect of milk products or milk
protein-derived peptides on the development of hypertension, SBP was
measured weekly using a tail-cuff blood pressure analyser (IITC Life Science,
Model 179, Woodland Hills, CA, USA). Before the measurement, the rats were
kept at 30°C for 30 min to enable pulsations of the tail artery to be detected.
When three consecutive measurements were obtained without disturbance of
the signal, the arithmetic mean was recorded as the SBP.
4.4 ARTERIAL FUNCTION
4.4.1 Arterial preparations (Studies II, IV, unpublished data)
In the studies examining the effects of milk protein-derived peptides on arterial
function, the superior mesenteric artery was carefully excised and cleaned of
adherent connective tissue. Sections of 3 mm in length were cut 5 mm distally
from the mesenteric artery-aorta junction. The rings were placed between
stainless steel hooks and mounted in an organ bath chamber in Krebs-Ringer
buffer (pH 7.4) and aerated with O2/CO2 (96%/4%). The rings were initially
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equilibrated for 45 min at 37°C with a resting tension of 1.0 g. The force of
contraction was measured with an isometric force displacement transducer and
registered with a polygraph (FTO3 transducer, Model 7P122E Polygraph; Grass
Instrument Co, Quincy, MA, USA). Acetylcholine (ACh; 1 µM) -induced
relaxation after noradrenaline (NA; 1 µM) precontraction was used to test the
presence or absence of endothelium.
4.4.2 Arterial responses in the presence of α-lactorphin or β-lactorphin
(Study II)
The effects of α-lactorphin or β-lactorphin on the cumulative relaxation
response to ACh (1 nM−10 µM) and sodium nitroprusside (SNP) (1 nM−10 µM)
were determined. After a 15-min incubation with the tetrapeptides (0.1 mM) or
vehicle, the mesenteric artery preparations were precontracted with NA (1 µM)
before administration of ACh or SNP. ACh and SNP were added only after the
precontraction or the previous level of relaxation was stable. After the maximal
relaxation response was reached, rings were rinsed with Krebs-Ringer buffer
and allowed at least a 30-min recovery period at the resting tension before the
next response curve. Cumulative responses to ACh were also elicited in the
presence of 0.1 mM L-NAME (a non-selective inhibitor of NOS), L-NAME in
combination with 1 mM tetraethylammonium tetrahydrate (TEA; a non-selective
inhibitor of potassium channels), and 3 µM diclofenac (a non-selective inhibitor
of cyclooxygenase).
4.4.3 Arterial responses after long-term intake of milk products
(unpublished data)
After the long-term intake of various milk products (Study III), cumulative
relaxation responses to ACh and SNP (1 nM−10 µM) were examined after NA
precontraction (1 µM). Cumulative concentration-response curves were
determined for NA (1 nM−0.1 mM) and potassium chloride (KCl, 20−125 mM).
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In the experiments with KCl, NaCl was replaced with KCl on an equimolar basis
to maintain a constant osmolality.
4.4.4 Functional bioassay of ACE inhibitory activity (Study IV)
The arterial rings were prepared as described in the section 4.4.1. The ACE
inhibitory activity of IPP and VPP (0.1–3.3 mM) and captopril (10 µM) was
assayed in vitro by preincubating mesenteric artery preparations with test
substances for 15 min and measuring the response to a single administration of
0.1 µM angiotensin I or 0.1 µM angiotensin II. Angiotensins were administered
only once to avoid tachyphylaxis (Khairallah et al. 1996).
4.5 COLLECTION OF SAMPLES
During the last week of the long-term experiments the rats were housed
individually in metabolic cages (Studies III, IV). The consumption of freely
accessible feed and drinking fluid was measured, and the estimated intake of
electrolytes was estimated. Urine was collected over a 24-h period, urine
volumes were measured and the samples were stored at -80ºC until the
biochemical determinations were performed.
At the end of experiments (Studies III, IV), the animals were rendered
unconscious with CO2/O2 (70%/30%; AGA, Riihimäki, Finland) and decapitated.
Blood samples were taken into chilled tubes in ice using EDTA as an
anticoagulant for plasma renin activity measurements (Study III).
4.6 BIOCHEMICAL DETERMINATIONS
The peptide contents of the fermented milk products and feed were determined
by the modified method of Masuda et al. (1996), in which the peptide fraction
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was collected by gel filtration chromatography (Superdex Peptide HR 10/30,
Amersham Pharmacia Biotech, UK) and analysed by reversed phase high
performance liquid chromatography (HPLC) at 214 nm (Novapak C18, Waters
Alliance HPLC, UV, USA). The electrolyte compositions of the fermented milk
products were determined by atomic absorption spectrophotometry (Philips PU
9400X atomic absorption spectrophotometer, flame detection, UK) (Studies III,
IV).
Plasma renin activity (Study III) was determined by radioimmunoassay (Medix
Angiotensin I test®, Medix Biochemica, Kauniainen, Finland). Urine sodium and
potassium concentrations were measured by flame photometer using an ion-
selective electrode compensator (human serum pool, IL model 943,
Instrumentarium Laboratory, Milan, Italy) (Burtis et al. 1975). Urine calcium and
magnesium were determined by flame atomic absorption spectrometry (Cali et
al. 1973) (Studies III, IV).
The ACE-inhibitory activity was measured by a spectrophotometric assay
(Cushman & Cheung 1971, with modifications of Nakamura et al. 1995a) (Study
I). The method is based on the liberation of hippuric acid from hippuryl-L-
histidyl-L-leucine (Hip-His-Leu) catalysed by ACE. After a 30-min incubation at
37°C, the hippuric acid was extracted with ethyl acetate and measured
spectrophotometrically (Perkin Elmer Lambda Bio UV/VIS Spectrometer,
Germany).
4.7 COMPOUNDS
α-Lactorphin (Tyr-Gly-Leu-Phe) and β-lactorphin (Tyr-Leu-Leu-Phe) were
synthesized and supplied by the Agrifood Research Finland, Food Research
(Jokioinen, Finland). The solid-phase peptide synthesis by the 9-
fluorenylmethoxycarbonyl chemistry (Fmoc method) was carried out on a semi-
automatic peptide synthesizer (Nova-Syn Gem, Calbiochem-Novabiochem,
Switzerland). Reversed phase HPLC was used to purify the peptides.
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Ile-Pro-Pro and Val-Pro-Pro were obtained commercially (Peninsula
Laboratories Europe Ltd, St. Helens, UK).
α-Lactalbumin was isolated from a bovine whey protein concentrate.
α-Lactalbumin was separated from β-lactoglobulin using pH adjustment, heat
treatment and centrifugation (Tupasela et al. 1997). Total protein was analysed
by the Kjeldahl method, and the purity of individual protein fractions was
assessed by ion exchange chromatography (Humprey & Newsome 1984).
Peptic hydrolysate of α-lactalbumin was produced by dissolving the freeze-
dried protein in hydrogen chloride and hydrolysing it with pepsin. After
hydrolysis, the pH of the mixture was adjusted by adding sodium hydroxide.
Finally the mixture was cooled and freeze-dried.
The fermented milk products A (Study III) and C (Study IV) were manufactured
from skim milk that was heat-treated (110°C/10 min) and inoculated with 10%
of Lactobacillus helveticus (LBK16H strain). The milk was fermented for 24 h at
37°C. Fermented milk B (Calpis®) was obtained commercially from The Calpis
Food Industry Co. Ltd, Tokyo, Japan (Study III). The starter culture for
fermented milk B has been reported to contain Lactobacillus helveticus and
Saccharomyces cerevisiae (Nakamura et al. 1995a). Energy, nutrient and
electrolyte contents in the milk products and feed are presented in Table 7.
In addition, the following compounds were used: acetylcholine chloride,
angiotensin I acetate, angiotensin II acetate, captopril, diclofenac, L-glycine
hydrochloride, L-leucine, NG-nitro-L-arginine methyl ester hydrochloride,
noradrenaline bitartrate, L-phenylalanine, sodium nitroprusside dihydrate,
tetraethylammonium tetrahydrate, L-tyrosine hydrochloride (Sigma Chemical
Co, MO, USA), ampicillin (A-Pen®, Orion, Finland), buprenorphin (Temgesic®,
Reckitt & Colman, UK), fentanyl-fluanisone (Hypnorm®, Janssen
Pharmaceutica, Belgium), HOE140 (icatibant; D-Arg0[Hyp3,Thi5,D-
Tic7,Oic8]bradykinin; Hoechst AG, Germany), midazolam (Dormicum®,
Hoffmann - La Roche, Switzerland) and naloxone hydrochloride (Endo
Laboratories, NY, USA).
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All compounds given to animals subcutaneously or intraperitoneally were
dissolved in physiological saline (0.9% NaCl). Orally administered Ile-Pro-Pro
and Val-Pro-Pro were dissolved in tap water. Compounds used in the in vitro
experiments were dissolved in distilled water, except for α-lactorphin and
β-lactorphin, which were dissolved in Krebs-Ringer buffer, and TEA, which was
dissolved in dimethylsulfoxide (DMSO) (96%). All solutions were freshly
prepared before use and protected from light.
4.8 STATISTICAL ANALYSIS
The values are expressed as means ± SEM. One-way analysis of variance
(ANOVA) followed by Tukey’s test was used when carrying out pairwise
comparisons between the treatment groups. Comparisons to baseline were
performed by Student’s t test (Study I). Mann-Whitney U test was used to
compare the differences between SHR and WKY (Study I). Data for relaxation
responses, presented as a percentage of precontraction level (Study II), and for
SBP (Studies III, IV) were analysed by two-way ANOVA with repeated
measures for overall treatment effect. P<0.05 was considered statistically
significant.
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Table 7. Contents of energy, nutrients, electrolytes and tripeptides IPP and VPP
in different drinking fluids and feed in the long-term experiments (Studies III, IV).
Water IPP & Skim Fermented Fermented Fermented Feed
VPP milk milk A milk B milk C
Study III, IV IV III III III IV III, IV
Energy 0 0 34 36 48 43 301
kcal/100g
Protein 0 0 3.4 0.7 1.8 2.4 18.5
g/100g
Fat 0 0 0.08 0.07 0.04 0.49 4
g/100g
Carbohydrate 0 0 4.9 7.9 10 7.2 56
g/100g
Sodium 0.6 0.6 44 88 66 26 275
mg/100g
Potassium 0.2 0.2 160 320 94 150 600
mg/100g
Calcium 2.1 2.1 120 440 66 330 980
mg/100g
Magnesium 0.2 0.2 12 21 6.6 33 200
mg/100g
IPP 0 16−30 UDL 14−16 6−8 16−18 0
mg/l
VPP 0 16−30 UDL 20−26 10−12 16−18 0
mg/l
UDL, under detection limit
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5 RESULTS
5.1 EFFECTS OF α-LACTORPHIN AND β-LACTORPHIN ON BLOOD
PRESSURE (Study I, unpublished data)
α-Lactorphin (s.c.) dose-dependently decreased blood pressure in conscious
SHR (Study I). The lowest effective dose was 10 µg/kg. Maximal reductions in
SBP (23±4 mmHg from the baseline value of 166±5 mmHg) and DBP
(17±4 mmHg from baseline of 111±4 mmHg) were obtained after 100 µg/kg of
α-lactorphin; no further reductions were observed at a higher dose of 1 mg/kg.
The decrease in blood pressure after 100 µg/kg of α-lactorphin was maximal
within 50−100 min and returned to baseline within 200 min. Heart rate was not
significantly influenced by α-lactorphin.
Maximal reductions in SBP and DBP by α-lactorphin (100 µg/kg s.c.) in
normotensive WKY were 16±3 mmHg and 12±3 mmHg, respectively (from
baseline values of 128±3 mmHg and 86±4 mmHg) (Study I). The depressor
effect was not enhanced with a larger dose of α-lactorphin (1 mg/kg). Although
the responses to α-lactorphin were somewhat weaker in WKY than in SHR, no
significant differences were observed in the magnitude of blood pressure
decreases between the rat strains.
β-Lactorphin (1−100 µg/kg s.c.) decreased blood pressure in conscious SHR
(Table 8). β-Lactorphin at a dose of 100 µg/kg lowered SBP maximally by
17±1 mmHg and DBP by 13±2 mmHg (from baseline values of 167±3 mmHg
and 114±4 mmHg, respectively). Due to the weak solubility of β-lactorphin,
effects of doses larger than 100 µg/kg could not be investigated.
The single constituent amino acids of 100 µg/kg α-lactorphin or β-lactorphin
(L-tyrosine, L-glycine, L-leucine, L-phenylalanine) did not significantly affect
blood pressure after subcutaneous administration in SHR at the maximal doses
released from the peptides (Study I).
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TABLE 8. Effect of β-lactorphin (s.c.) on blood pressure (BP) in SHR
(unpublished data).
Baseline (mmHg) Maximal change in BP (mmHg)
Treatment SBP DBP SBP ∆ DBP ∆
Saline 1 ml/kg 165±4 115±3 170±7    6±8 114±5   -1±5
β-Lactorphin 1 µg/kg 167±6 118±3 155±7 -13±6 107±6# -11±4
β-Lactorphin 10 µg/kg 164±2 114±3 150±4# -15±4 101±2### -13±1
β-Lactorphin 100 µg/kg 167±3 114±4 150±3### -17±1* 102±4### -13±2
Values are presented as mean ± SEM, n=6−8.
*P<0.05 vs. saline, #P<0.05, ##P<0.01, ###P<0.001 vs. baseline.
The opioid receptor antagonist naloxone did not affect blood pressure in SHR at
doses of 0.3 and 1 mg/kg s.c., whereas a significant decrease in both SBP and
DBP was observed after 3 mg/kg (Study I). Pretreatment with naloxone dose-
dependently did, however, antagonize the decrease in blood pressure induced
by α-lactorphin (100 µg/kg). After a large dose of naloxone (3 mg/kg),
subsequent administration of α-lactorphin increased SBP by 28±6 mmHg
(P<0.001) and DBP by 24±5 mmHg (P<0.01).
The ACE inhibitor captopril lowered SBP by 24±4 mmHg and DBP by 16±4
mmHg at a dose of 10 mg/kg s.c. in SHR, whereas lower doses of captopril
(1 µg/kg−1 mg/kg s.c.) did not significantly influence blood pressure (Study I).
Bradykinin B2-receptor antagonist HOE140 (250 µg/kg s.c.) did not have a
significant effect on blood pressure (Study I). Furthermore, pretreatment with
HOE140 failed to significantly influence the blood pressure response to
α-lactorphin (100 µg/kg s.c.).
The concentrations of α-lactorphin and captopril needed to inhibit 50% of ACE
activity (IC50) were measured spectrophotometrically. The IC50 value obtained
for α-lactorphin was 1 260 µmol/l (630 mg/l) and for captopril 0.007 µmol/l
(1.5 µg/l). These values are in accordance with those reported previously
(Mullally et al. 1996).
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5.2 EFFECT OF α-LACTALBUMIN ON DEVELOPMENT OF HYPERTENSION
(unpublished data)
Long-term oral intake of α-lactalbumin (255 mg/kg) did not influence the
development of hypertension in young SHR measured by radiotelemetry
(Figure 2). SBP rose gradually during the experiment in all groups (Figure 2). In
the group that received peptic hydrolysate of α-lactalbumin (255 mg/kg), blood
pressure increased slightly but not significantly as compared with the water
group. After the 12-week treatment period, SBP and DBP values in the water
group were 166±3 mmHg and 125±5 mmHg, in the group receiving
α-lactalbumin 172±4 mmHg and 130±6 mmHg, and in the group receiving
peptic hydrolysate of α-lactalbumin 185±4 mmHg and 139±4 mmHg,
respectively.
Figure 2. Long-term intake of α-lactalbumin or peptic hydrolysate of α-
lactalbumin showed no influence on development of hypertension in young SHR
as measured by radiotelemetry. The baseline SBP and DBP values were 142/101
mmHg in the water group, 143/100 mmHg in the group receiving α-lactalbumin and
145/102 mmHg in the group receiving the peptic hydrolysate of α-lactalbumin
(unpublished data).
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5.3 EFFECTS OF α-LACTORPHIN AND β-LACTORPHIN ON ARTERIAL
FUNCTION (Study II)
Endothelium-dependent relaxation evoked by ACh was significantly depressed
in mesenteric arteries of adult SHR as compared with the relaxation response
in vessels of normotensive WKY (Study II). In SHR, maximal relaxation to ACh
(32±8% of the precontraction level) was observed at 1 µM ACh. A higher
concentration of ACh elicited a slight contraction in the arterial preparations. In
WKY, maximal relaxation to ACh (93±2% of the precontraction level) was
measured at 10 µM ACh.
In arterial preparations obtained from SHR, the relaxation response to ACh was
improved by preincubation with α-lactorphin or β-lactorphin (to 49±8% and
61±8% of the precontraction level, respectively). In arterial preparations from
WKY, this effect of α-lactorphin or β-lactorphin was not observed (90±6% and
93±2% of precontraction level) (Study II). α-Lactorphin or β-lactorphin had no
effect on the vascular tone of quiescent mesenteric arterial preparations of SHR
or WKY.
To study the influence of different endothelium-derived factors on the effect of
α-lactorphin or β-lactorphin in SHR, the cumulative response curve to ACh was
elicited in the presence of the NOS inhibitor L-NAME, L-NAME combined with
the potassium channel inhibitor TEA, and cyclooxygenase inhibitor diclofenac
(Study II). L-NAME abolished the improvement in the ACh relaxation induced by
α-lactorphin or β-lactorphin in mesenteric arterial preparations of SHR. The
simultaneous addition of TEA to the organ bath did not elicit further dilation.
Cyclooxygenase inhibition with diclofenac did not reduce the improvement in
ACh relaxation induced by α-lactorphin or β-lactorphin. In fact, diclofenac
tended to augment the response to ACh in the arterial preparations of SHR.
Neither L-NAME, diclofenac nor TEA had a direct relaxant or contractile effect
on vascular tone.
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Endothelium-independent relaxation to SNP in mesenteric arterial rings did not
differ between SHR and WKY. In SHR, the SNP-induced relaxation dose-
response curve was shifted to the left in the presence of β-lactorphin (Study II).
However, the maximal relaxation response to SNP was unaffected by the
tetrapeptide. Endothelium-independent relaxation was also unaffected by
α-lactorphin. In WKY, the tetrapeptides had no effect on the relaxation induced
by SNP.
5.4 EFFECTS OF MILK PRODUCTS AND MILK-DERIVED TRIPEPTIDES IPP
and VPP ON DEVELOPMENT OF HYPERTENSION IN SHR (Studies III, IV)
5.4.1 Blood pressure
In long-term studies investigating the effect of IPP and VPP on development of
hypertension in young prehypertensive SHR, SBP rose gradually during the
experiments. After 10 weeks of treatment, the blood pressure persisted at a
stabile hypertensive level in all groups in both experiments (Studies III, IV).
In the groups receiving tripeptides IPP and VPP (Study IV) or fermented milk
products containing the tripeptides (Studies III, IV), the development of
hypertension was attenuated as compared with the groups receiving water.
After the treatment period, SBP was 12 mmHg lower in the group receiving
tripeptides IPP and VPP (181±2 mmHg) than in the water group (193±1 mmHg)
(Study IV). In the groups receiving fermented milk containing IPP and VPP,
SBP levels were significantly lower than in water groups. In Study III, SBP
values after the 12-week treatment period were 176±1 mmHg in the group
receiving the whey of fermented milk A, 186±1 mmHg in the group receiving
fermented milk B and 197±1 mmHg in the water group. At the end of Study IV,
SBP was 176±1 mmHg in the group receiving fermented milk C and
193±1 mmHg in the water group. Skim milk had no effect on the development
of hypertension in young SHR (Study III).
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In Study IV, SBP was monitored four weeks after treatment withdrawal to
examine whether the attenuation of hypertension development was due to the
treatments. In the groups receiving the tripeptides or fermented milk C, the SBP
rose gradually after the treatment withdrawal reaching the level of the control
group within the four weeks.
5.4.2 Arterial function (unpublished data)
The effect of long-term intake of milk products on arterial function was
determined. Maximal relaxation responses to ACh and SNP and contraction
forces to NA and KCl are presented in Table 9. The maximal relaxation
responses were observed at 1 µM ACh and 10 µM SNP. The maximal
contractions were measured at 0.1 mM NA and 125 mM KCl.
TABLE 9. Maximal relaxation responses and contraction forces after long-term
intake of milk products in SHR (unpublished data)
Maximal relaxation (%) Maximal contraction (g)
Treatment ACh SNP NA KCl
Water 24 ± 5 89 ± 2 1.96 ± 0.1 1.92 ± 0.2
Skim milk 33 ± 3 91 ± 2 1.94 ± 0.1 1.91 ± 0.1
Fermented milk A 36 ± 5 97 ± 1* 1.87 ± 0.1 1.63 ± 0.1
Fermented milk B 40 ± 3 93 ± 1 1.80 ± 0.2 1.55 ± 0.1
Values are mean ± SEM, n=6−10.  * P<0.05 vs. water. ACh, acetylcholine; SNP, sodium
nitroprusside; NA, noradrenaline; KCl, potassium chloride.
5.4.3 ACE inhibitory activity (Study IV)
In the functional bioassay evaluating the ACE inhibitory activity of IPP and VPP,
angiotensin I (0.1 µM) contracted mesenteric arterial preparations similarly to
angiotensin II (0.1 µM). The angiotensin I-induced contraction was abolished by
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preincubation with the ACE inhibitor captopril (10 µM). IPP also dose-
dependently inhibited the angiotensin I-induced contraction (Figure 3); the
smallest effective concentration was 1 mM. The largest concentration of IPP
(3.3 mM) abolished the contraction response to angiotensin I, while the
angiotensin II-induced contraction remained unaffected. VPP of up to 3.3 mM
had no effect on the angiotensin I contraction in this experimental setting.
Figure 3. Effects of IPP and VPP on angiotensin I- and angiotensin II-induced
contractions in mesenteric artery preparations of Wistar rats compared with the
effects of captopril and control. Values are mean ± SEM (n=6–8 in each group).
**P<0.01, ***P<0.001 vs. control. ANG I, angiotensin I; ANG II, angiotensin II. Control,
open bars; IPP, cross-hatched bars; VPP, hatched bars; captopril, solid bar.
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5.4.4 Body weight gain, consumption of drinking fluid and feed, estimated
intake of electrolytes and tripeptides IPP and VPP (Studies III, IV)
In the groups receiving fermented milk products A and B (Study III), the intake
of IPP and VPP varied due to different peptide contents in the milk products
and different consumption of each product. The approximate calculated intake
of IPP in the groups receiving fermented milk products A and B was 0.4 mg/day
and 0.2 mg/day, respectively, whereas the corresponding intakes of VPP were
0.6 mg/day and 0.3 mg/day.
The intakes of IPP and VPP in the group receiving fermented milk C (Study IV)
were calculated based on the daily consumption of the product. In the group
receiving IPP and VPP, the intakes of the tripeptides were adjusted to
correspond to the intakes in the group receiving fermented milk C. The intakes
of IPP and VPP in both groups were 2.5–3.5 mg/kg/day (Study IV).
Intake of IPP and VPP had no effect on body weight gain, consumption of
drinking fluid or feed, or the estimated intake of electrolytes (Study IV).
The consumption of milk products varied depending on the product. In the
groups that consumed large amounts of the milk product, such as the skim milk
(Study III) or fermented milk C (Study IV), the consumption of feed was low.
Thus, the daily energy intakes between the study groups did not differ. Body
weight gain was slightly attenuated in the groups receiving fermented milk
products A and B (Study III). Due to the different compositions of the milk
products, the estimated intake of electrolytes and nutrients differs between the
groups (Table 10).
5.4.5 Urinary volume and electrolyte excretion (Studies III, IV)
Intake of the tripeptides IPP and VPP had no effect on urinary volume or urinary
excretion of electrolytes (Study IV).
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In the groups receiving milk products, the urinary volume and the urinary
excretion of sodium, potassium, magnesium and calcium were closely related
to the estimated intakes of these electrolytes (Table 10). Due to differences in
the electrolyte compositions between the milk products, the intakes of
electrolytes, and thus, the urinary excretions of electrolytes, differ between the
groups (Table 10).
5.4.6 Plasma renin activity (Study III)
Plasma renin activity was increased in groups receiving fermented milk
products A and B (4.4±0.5 and 4.6±0.5 ng angiotensin I/ml/h, respectively) as
compared with the groups receiving water (1.4±0.3 ng angiotensin I/ml/h) and
skim milk (2.6±0.4 ng angiotensin I/ml/h).
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Table 10. Body weight gain, consumption of feed and drinking fluid, estimated
intake of energy, nutrients and electrolytes, urine volume and urinary excretion
of electrolytes in long-term experiments III and IV.
Water Skim Fermented Fermented Water Peptides Fermented
milk milk A milk B milk C
Study III III III III IV IV  IV
Body weight, g 134±1 132±1 134±2 132±2 138±4 138±5 137±5
baseline
Body weight, g 342±4 356±4 310±9†§ 294±7†§ 333±8 334±5 324±10
end of experiment
Feed intake, g/d 22±1 16±1† 17±1 14±2† 17±1 17±1 6±1*
Drink intake, g/d 32±3 55±3† 27±1§ 25±1§ 33±2 31±3 64±2*
Estimated intake of
Sodium 62±3 69±4 71±4 56±6 48±3 46±2 34±2*
mg/d
Potassium 134±7 185±10† 190±8† 109±13§ 104±6 99±4 132±5*
mg/d
Calcium 220±12 224±13 287±13†§ 156±22†§ 171±9 162±7 270±9*
mg/d
Magnesium 45±2 39±2 40±3 30±4† 35±2 33±1 33±1
mg/d
Urine
Volume 11±2 19±2† 4±1† 8±1 10±1 12±2 35±2*
ml/d
Sodium 27±2 33±2 27±2 30±2 26±1 23±1 22±2
mg/d
Potassium 76±5 122±4† 85±4§ 63±4§ 56±8 53±9 114±4*
mg/d
Calcium 0.7±0.1 1.6±0.2 2.3±0.5† 1.7±0.3 0.6±0.1 0.7±0.1 9.7±0.6*
mg/d
Magnesium 3.6±0.5 2.1±0.7 5.2±0.5§ 4.6±0.7§ 3.6±0.4 3.8±0.4 11±0.3*
mg/d
†
 P<0.05 vs. water (Study III)
§
 P<0.05 vs. skim milk (Study III)
* P<0.05 vs. water and IPP & VPP (Study IV)
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6 DISCUSSION
Epidemiological evidence implies that consumption of milk and dairy products is
inversely associated with blood pressure and the risk for hypertension.
Therefore, this study investigated the effect of milk products and milk protein-
derived peptides on blood pressure, development of hypertension and arterial
function using SHR as the experimental model for hypertension. Mechanisms
underlying the effects of milk products and peptides were also studied.
6.1 METHODOLOGICAL ASPECTS
SHR is the most widely studied animal model for human essential hypertension.
SHR is an inbred rat strain that readily develops hypertension and its
complications with increasing age. Despite the frequent use of SHR, this strain
has occasionally been criticized as being an inappropriate model for human
essential hypertension (for review, see Zicha & Kunes 1999). Indisputedly, the
comparison of human essential hypertension with genetic hypertension of the
rat is complex because the species differ in their genetic defects and gene-
environment interactions. Nevertheless, the basic principles regarding
development of hypertension in rats and humans are surprisingly similar (for
review, see Zicha & Kunes 1999). Normotensive WKY are generally used as a
control for SHR, even though some of the physiological and biochemical
differences between the strains are likely to be unrelated to hypertension
(Lindpaintner et al. 1992). These differences are due to the selective breeding
of SHR, in which the desired phenotype (spontaneous hypertension) in the
selected individuals has coincidentally been accompanied by other genetic
characteristics, which have, therefore, also become fixed in the hypertensive
inbred strain. To date, however, WKY are considered an appropriate
normotensive control rat strain for SHR.
In the present study, blood pressure was measured either directly by
radiotelemetry or indirectly by the tail-cuff method. Radiotelemetric
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measurements provide the possibility of obtaining continuous, high-fidelity
recordings of blood pressure for relatively long periods of time. In addition,
the method allows blood pressure monitoring in conscious, freely moving
animals without the need for restraints or anaesthesia. The main limitation
of this method is the drift in telemeter settings and sensitivity. A
recalibration of the telemeter device immediately before implantation is
therefore essential to ensure the accuracy of blood pressure measurements (for
review, see van Vliet et al. 2000). Maintenance of the method is also relatively
expensive.
When a study design requires monitoring of a large number of animals over a
long time period, the non-invasive tail-cuff method is commonly chosen, as in
the present study. The indirect tail-cuff recording of blood pressure shows good
correlation with direct recordings using intra-arterial catheters in rats (Bunag &
Butterfield 1982). It may, however, overestimate blood pressure levels (Bazil et
al. 1993). The inevitable use of restraints produces a stress artefact manifesting
as elevated plasma catecholamines and cortisol (Kvetnansky et al. 1977). In
addition, to obtain reliable SBP values via the tail-cuff method, the animals
require warming prior to actual measurement. This obviously causes further
stressful stimuli and may influence blood pressure (Kenney et al. 1995).
Another limitation of the tail-cuff method is that it reliably produces only SBP
values.
The arteries of SHR and patients with essential hypertension have alterations in
the structure and function caused by sustained hypertension (Hollenberg 2000).
Some degree of vascular structural alterations have already been observed in
young 3- to 4-week-old SHR even when blood pressure is similar to that in age-
matched WKY (Rizzoni et al. 1994; Dickhout & Lee 1997). However, structural
changes in the superior mesenteric artery have become evident only in older
SHR (16- to 28-week-old) with established hypertension (Lee et al. 1983; Lee
1987). The structural alterations of blood vessels manifest functionally as
impaired endothelium-dependent vasodilator responsiveness. In young SHR,
the relaxation response to ACh is similar to that in WKY, whereas in older SHR
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with established hypertension as in our study, it is impaired (Dohi et al. 1990;
Fujii et al. 1993; Rizzoni et al. 1994).
The major complications of hypertension result from the affliction of relatively
large arteries (for review, see Safar et al. 1998). The effects of different
antihypertensive interventions on the function of conduit arteries are therefore
of importance. In this study, the main superior mesenteric artery was used as a
model of a conduit artery. It is highly suitable for organ bath studies because it
produces a stable precontraction, and its diameter (1-1.5 mm) allows
preparation without a microscope. The mesenteric arteries of normotensive
WKY were used as a model of arteries with normal functional structure.
6.2 EFFECTS OF α-LACTORPHIN AND β-LACTORPHIN ON BLOOD
PRESSURE AND ARTERIAL FUNCTION
α-Lactorphin and β-lactorphin, originally derived from milk whey proteins
α-lactalbumin and β-lactoglobulin, respectively, lowered blood pressure in adult
SHR. The antihypertensive effect of the tetrapeptides was not attributable to the
constitutive amino acids L-tyrosine, L-glycine, L-leucine or L-phenylalanine.
Both α-lactorphin and β-lactorphin have been reported to bind to opioid
receptors in a radioreceptor assay (Yoshikawa et al. 1986; Antila et al. 1991). In
addition, the structures of α-lactorphin and β-lactorphin closely resemble the
amino terminal amino acid sequence of most endogenous opioid peptides
(Tyr-Gly-Gly-Phe-) (Table 5). In this study, opioid receptor antagonist naloxone
dose-dependently inhibited the antihypertensive action of α-lactorphin,
suggesting that opioid receptors were involved in the blood pressure-lowering
effect of α-lactorphin. Naloxone is a non-selective opioid antagonist that mainly
blocks the effect of opioids on µ-receptors. At large doses, however, it also
inhibits the effects mediated via δ- and κ-opioid receptors (Chang &
Cuatrecasas 1979; Leslie 1987). Any subtype of opioid receptors may,
therefore, be responsible for the depressor effect of α-lactorphin.
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Pretreatment with naloxone not only antagonized the decrease in blood
pressure induced by α-lactorphin, but a large dose of naloxone reversed it into
a pressor response. An increase in blood pressure during the presence of
naloxone has been observed with other antihypertensive agents, such as
alpha-methyldopa and clonidine (Farsang et al. 1984; Kunos et al. 1984). The
pressor effect has been suggested to be due to noradrenergic vasoconstriction
since it was associated with increased plasma concentration of catecholamines
(Farsang et al. 1984). Furthermore, the effect was blocked by α1-adrenoceptor
antagonist prazosin (Kunos et al. 1984). In anaesthetized rats, large doses of
naloxone have also been shown to potentiate the pressor response to
catecholamines (Feria et al. 1990). However, no experimental evidence exists
that α-lactorphin could release catecholamines, and the mechanism of the
increase in blood pressure by α-lactorphin after naloxone pretreatment remains
undetermined.
Many of the known effects of opioids (e.g. sedation, analgesia) are mediated
via the central nervous system. The level (central vs. peripheral) of the
depressor response to α-lactorphin was not determined in this study. However,
a peripheral site of action is feasible because it is unlikely that
α-lactorphin as a tetrapeptide could easily cross the blood-brain barrier.
Endogenous opioids and opioid receptors are present in some peripheral
tissues, including the sympathetic ganglia, adrenal medulla and vascular
endothelium (Hughes et al. 1977; Viveros et al. 1979; Cadet et al. 2000). In
rats, intravenous administration of morphine has elicited a depressor response
that depended on peripheral opioid receptor activation (Randich et al. 1993). In
addition, peripherally administered endogenous opioid peptides, such as
endomorphins, have lowered blood pressure in rats (Champion et al. 1997).
α-Lactorphin and β-lactorphin improved endothelium-dependent relaxation to
ACh of mesenteric arteries of adult SHR with established hypertension in vitro.
NOS inhibitor L-NAME abolished the improvement, suggesting an involvement
of NO in this action. Endogenous opioid peptides, endomorphins and met-
enkephalin have also produced vasorelaxation in rats in a NO-dependent
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manner (Champion & Kadowitz 1998, 1999; Wilderman & Armstead 1998).
Opioid receptor stimulation in the vascular endothelium has been proposed to
release NO (Stefano et al. 1998).
The COX inhibitor diclofenac did not influence the improved relaxation
response to ACh in the presence of α-lactorphin and β-lactorphin. This
suggests that vasodilatory prostanoids were not involved. The vasodilator
response elicited by endomorphins has also not been mediated by vasodilatory
prostanoids (Champion & Kadowitz 1998; Champion et al. 1998). The
relaxation response to ACh in the presence of the tetrapeptides tended to
enhance after diclofenac pretreatment in our study. Production of
vasoconstrictory prostanoids, such as prostaglandin F2α, prostaglandin H2 or
thromboxane A2, is increased in adult SHR (Matrougui et al. 1997; Kagota et al.
1999; Zhou et al. 1999), which may explain this finding.
The effect of TEA on ACh-induced relaxation of mesenteric arterial
preparations was negligible in the presence of α-lactorphin and β-lactorphin.
TEA is a non-selective potassium channel blocker that inhibits the EDHF-
induced hyperpolarization and the subsequent smooth muscle relaxation. When
administered to the organ bath simultaneously with L-NAME, TEA elicited no
additional effect. This suggests that EDHF did not play a major role in the
vascular effects of α-lactorphin or β-lactorphin in our experimental setting.
Likewise, opening of the potassium channels was presumably not involved in
the vasodilatory action of endomorphins (Champion & Kadowitz 1998;
Champion et al. 1998).
β-Lactorphin improved the endothelium-independent relaxation response to
SNP in SHR, whereas α-lactorphin had no effect on SNP-induced relaxation.
This finding suggests that the improvement in the vascular function induced by
β-lactorphin may be mediated not only by the endothelium, but that vascular
smooth muscle may also be directly influenced. β-Lactorphin may increase the
ability of vascular smooth muscle to relax in response to NO-donors, whereas
α-lactorphin does not seem to enhance sensitivity of the smooth muscle to NO.
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α-Lactorphin and β-lactorphin have been shown to possess ACE inhibitory
activity in vitro (Mullally et al. 1996). This was also observed in the present
study. However, as compared with captopril, whose IC50 value was within
nanomolar range, the ACE inhibitory activity of the tetrapeptides was very
weak, with IC50 values at millimolar level. In contrast, a comparable decrease in
blood pressure was seen with 200-fold lower doses of α-lactorphin than of
captopril. Since ACE is also involved in the breakdown of bradykinin, increased
bradykinin levels are suggested to have a role in the antihypertensive action of
ACE inhibitors (Brown & Vaughan 1998). Because blocking of bradykinin
B2-receptors with HOE140 did not attenuate the α-lactorphin-induced decrease
in blood pressure, the involvement of bradykinin in the effect of α-lactorphin
can, therefore, be ruled out.
Taken together, the data suggest that the antihypertensive effect and the
improvement of the endothelium-dependent relaxation in SHR induced by
α-lactorphin or β-lactorphin could be related to opioid receptors in the
endothelium. Inhibition of ACE activity does not seem to be the mechanism of
the depressor response to α-lactorphin or β-lactorphin.
α-Lactorphin is a peptide fragment, which contains the amino acid residues
50-53 of milk whey protein α-lactalbumin (Findlay & Brew 1972). The
tetrapeptide was originally released from α-lactalbumin by in vitro proteolysis
with pepsin and trypsin (Antila et al. 1991). Since α-lactorphin was able to
lower blood pressure, it was of interest to investigate whether α-lactalbumin or
a peptic hydrolysate of α-lactalbumin could also influence blood pressure in
SHR.
The dose of α-lactalbumin or peptic hydrolysate of α-lactalbumin was calculated
to contain the amount of α-lactorphin that elicited an antihypertensive effect in
adult SHR. Bovine milk contains 0.9 g/l of α-lactalbumin (for review, see
Hambraeus 1985), whereas the maximum yield of α-lactorphin from 1 g of
α-lactalbumin has been estimated as 39 mg (Meisel 1998). Thus, one litre of
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milk can be calculated to maximally yield 35 mg of α-lactorphin. Oral
bioavailability of α-lactorphin was assumed to be low, and only 1% of ingested
α-lactorphin was estimated to be absorbed from the intestine.
Long-term intake of α-lactalbumin failed to influence the development of
hypertension in young prehypertensive SHR in the present experimental
setting. This failure could have been due to the inability of α-lactorphin to
influence hypertension development. In addition, the tetrapeptide may have
been released from α-lactalbumin in amount insufficient to elicit an effect on
blood pressure. Inadequate absorption of α-lactorphin from the intestine is
another possible explanation for the lack of effect. The effect of long-term
intake of β-lactoglobulin, the source of β-lactorphin in milk, on the development
of hypertension was not investigated since β-lactoglobulin is a major allergen of
milk (for review, see Wal 1998). Therefore, implications of this protein in non-
pharmacological treatment of hypertension would be scarce. This does not,
however, rule out the possible use of β-lactorphin in the non-pharmacological
treatment of hypertension because hydrolysis of β-lactoglobulin markedly
reduces its allergenicity (Halken & Høst 1997).
6.3 EFFECTS OF IPP, VPP AND MILK PRODUCTS ON DEVELOPMENT OF
HYPERTENSION
Long-term oral administration of IPP and VPP attenuated the development of
hypertension in young prehypertensive SHR. Hypertension development was
also attenuated after long-term intake of fermented milk products containing
these tripeptides. After treatment withdrawal, the SBP rose to the level of the
control group, confirming that the antihypertensive effect was due to the
treatments.
Various long-term antihypertensive treatments, such as ACE inhibitors, calcium
channel blockers and beta-blockers, have improved relaxation responses in
SHR (Tolvanen et al. 1996; Mervaala et al. 1998). In our study, arterial function
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was evaluated in vitro after long-term oral intake of fermented milk products.
Distinct improvement of arterial function was not observed, although
endothelium-independent relaxation of mesenteric arteries was enhanced
slightly.
Skim milk had no effect on the development of hypertension or arterial function,
suggesting that a factor present in the fermented milk products but absent in
the skim milk might be responsible for the effect. Possible factors are peptides
IPP and VPP, which have been shown to possess antihypertensive properties
in SHR (Nakamura et al. 1995b, 1996). A fermented milk product containing
these tripeptides (Calpis®) has been reported to attenuate the development of
hypertension in SHR (Nakamura et al. 1996). As compared with Calpis®, which
was fermented milk B in our study, the antihypertensive effect of the whey of
another fermented milk containing IPP and VPP, i.e. product A, turned out to be
stronger. One possible explanation for this is that fermented milk A contained
twice the amount of IPP and VPP present in Calpis®. IPP and VPP have been
reported to dose-dependently lower blood pressure in SHR after acute oral
administration (Nakamura et al. 1995b). Intake of fermented milk products
containing IPP and VPP has also lowered blood pressure in mildly hypertensive
patients in two small clinical studies (Hata et al. 1996; Seppo et al. 2002). The
fermented milk product A seemed to attenuate the development of hypertension
slightly more than the product C, but comparisons are difficult for the obvious
reason that the effects of these products were not investigated in the same
study. If the effects of these two products differed, one possible underlying
factor could be the apparent difference between the products: fermented milk A
contained nearly exclusively the whey fraction, whereas product C also
contained the casein fraction. Some evidence implies that whey-based products
may influence blood pressure advantageously (Wu et al. 1998; Kawase et al.
2000).
The mechanism underlying the blood pressure-lowering effect of IPP and VPP
has been proposed to be ACE inhibition (Nakamura et al. 1995a, 1995b;
Takano 1998). These tripeptides have been reported to possess ACE inhibitory
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activity in a spectrophotometric assay (Nakamura et al. 1995a). In our functional
assay of ACE inhibitory activity, IPP and captopril inhibited the angiotensin I-
induced contraction of mesenteric arteries in vitro. The compounds had no
effect on the angiotensin II-induced contraction, and therefore, the involvement
of angiotensin receptors is unlikely. The alleviation of hypertension
development in SHR that received IPP and VPP from fermented milk products
was accompanied by elevated plasma renin activity, thus providing indirect
evidence of ACE inhibition. Treatment with ACE inhibitors raises plasma renin
activity due to the lack of negative feedback induced by angiotensin II (Brunner
et al. 1993). In agreement with our findings, ACE activity in the aorta of SHR
has been shown to be reduced after long-term intake of Calpis® (Nakamura et
al. 1996).
Some factors, however, oppose the hypothesis that ACE inhibition is the
mechanism underlying the effect of IPP and VPP. IC50 values determined
for the tripeptides have been 1000-fold larger than that for captopril, which
points to the significantly weaker ACE inhibitory activity of the tripeptides. In
addition, the ACE inhibitory potency of IPP was much weaker than that of
captopril in the functional assay since millimolar concentrations of IPP were
needed to inhibit the angiotensin I-induced contraction of rat mesenteric artery,
whereas captopril inhibited the contraction at a 300-fold lower concentration.
The ACE inhibitory activity of VPP in spectrophotometric assays is not
supported by our findings; in the functional bioassay for ACE inhibitory activity,
VPP failed to show any potential for inhibiting contraction induced by
angiotensin I.
To summarize, some evidence does lend support to the hypothesis that ACE
inhibition is involved in the antihypertensive effect of IPP and VPP. Some
additional mechanisms, however, are likely to be found in fermented milk
products that contain the tripeptides since fermented milk C was more effective
in alleviating the development of hypertension than similar amounts of IPP and
VPP alone. This could be due to several factors. Other peptides with effects on
blood pressure may have been produced during the enzymatic hydrolysis of
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milk proteins. Peptides may also absorb better from a milk hydrolysate than
from a water solution, as has been shown in the case of amino acids (Rérat et
al. 1988). In addition, certain cell wall polysaccharide fractions of lactic acid
bacteria used in the starter cultures of fermented milk products have been
suggested to lower blood pressure in SHR (Furushiro et al. 1993; Nakajima et
al. 1995).
Another element underlying the antihypertensive effect of fermented milk
products may have been the electrolytes that these products contain. Intakes of
calcium and potassium have been reported to attenuate the development of
hypertension in SHR (Wuorela et al. 1992; Wu et al. 1998; Civantos et al.
1999). The role of calcium cannot be excluded because the amount
of calcium in the fermented milks A and C was higher than in skim milk, nearly
reaching the level reported to influence development of hypertension (Pörsti et
al. 1990). However, an antihypertensive factor other than calcium
is suggested since the development of hypertension was attenuated in the
group receiving Calpis®, despite the intake of calcium in this group being lower
than in the skim milk group. The intake of potassium was comparable in
the groups receiving fermented milk A and skim milk, but since skim milk
failed to affect hypertension development, potassium was presumably not
a notable factor. As compared with other milk products, the sodium content
of fermented milk C was low and the sodium-potassium ratio for intake
or excretion was lowest in SHR receiving product C, which may have
resulted in greater attenuation of hypertension development. In this model
of essential hypertension, moderate intake of sodium has produced less
pronounced hypertension development than a high-sodium diet (Mervaala et
al. 1992). However, the antihypertensive effect of IPP and VPP is not likely
to be mediated via natriuresis or diuresis since long-term intake of
these tripeptides did not affect urinary excretion of sodium or urine volume.
In conclusion, despite the antihypertensive effect of IPP and VPP in SHR
after long-term intake of fermented milk products, factors such as calcium may
have a role as well.
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An important issue regarding the possible usefulness of milk protein-derived
peptides in non-pharmacological treatment of hypertension is whether
their bioavailability after oral administration is sufficient to elicit systemic effects
on blood pressure. Dipeptides and tripeptides can absorb from the
gastrointestinal tract, whereas the intestinal absorption of tetrapeptides in more
controversial (for reviews, see Silk et al. 1981, 1985; Webb et al. 1992). In
addition to the size of the peptide, the amino acid structure seems to be of
importance. For example, a Pro-Pro bond has been proposed to possess a high
degree of resistance to any mammalian proteolytic enzyme (for review, see
Vanhoof et al. 1995). In our long-term experiment, oral intake of IPP and VPP
attenuated  the development of hypertension in SHR. These tripeptides have
been detected from the abdominal aorta of SHR after a single oral
administration of a sour milk product containing the tripeptides (Masuda et al.
1996). Consequently, these milk protein-derived tripeptides might be absorbed
from the intestine in sufficient amounts to elicit effects on blood pressure.
Taken together, this experimental study using SHR as the model of essential
hypertension found that short-chain milk protein-derived peptides lowered blood
pressure, attenuated the development of hypertension and improved arterial
function by mechanisms related to opioid receptor stimulation or ACE inhibition.
Electrolyte composition of the fermented milk products may have provided
additional benefit.
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7 SUMMARY AND CONCLUSIONS
This study investigated the effects of various milk products and milk protein-
derived peptides on blood pressure, development of hypertension, and arterial
function using SHR as the experimental model for hypertension.
The main findings are as follows:
• α-Lactorphin and β-lactorphin, tetrapeptides originally derived from whey
proteins, lowered blood pressure in hypertensive SHR and in
normotensive WKY.
• The antihypertensive effect of α-lactorphin was related to opioid receptor
stimulation. ACE inhibition did not seem to be involved.
• α-Lactorphin and β-lactorphin improved arterial function in SHR in an
endothelium-dependent manner in vitro. NO played a central role in this
effect, whereas vasodilatory prostanoids and hyperpolarization appeared
not to be implicated.
• Long-term intake of IPP and VPP or fermented milk products containing
these tripeptides attenuated the development of hypertension in young
SHR. Skim milk and α-lactalbumin had no influence on hypertension
development.
In conclusion, in an experimental model of hypertension, certain fermented milk
products and milk protein-derived peptides lowered blood pressure, attenuated
the development of hypertension and improved arterial function. These findings
encourage further investigation as to whether milk peptides could be beneficial
in non-pharmacological treatment of essential hypertension.
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